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 Abstract 
Prostatic acid phosphatase (PAP) has been linked to prostate cancer since the mid-
1930s. The main research approach of PAP over that time has been based on its role in the 
human prostate. The regulatory mechanisms of expression of the PAP gene have also been 
studied, giving us information about the regulatory elements in the gene and the transcription 
factors that affect the gene expression in the prostatic tissue. However, little was known until 
recently about this protein’s role and physiological function in other tissues. Our group 
generated and used a PAP-deficient mouse and was able to show that PAP is expressed in 
dorsal root ganglia (DRG) and spinal cord in mice. This is the same protein as thiamine 
monophosphatase (TMPase) whose enzymatic activity has been used for five decades to mark 
primary sensory neurons. In these tissues, PAP acts as an ecto-5'-nucleotidase and is able to 
dephosphorylate AMP to adenosine, and therefore produce an anti-nociceptive effect due to 
the binding of adenosine to the A1-adenosine receptor. 
We analyzed the ACPP gene, which enabled us to describe a new transmembrane 
isoform for PAP (TMPAP). This novel PAP isoform is produced by alternative splicing of 
the 11th exon of the ACPP gene. The alternative splicing is present in species such as the 
human, mouse and rat. The newly discovered isoform is widely expressed in human and 
mouse tissues and contains a tyrosine sequence (YxxΦ) in its carboxyl-terminus, which 
directs the protein to endocytosis. We have also corroborated its functionality by co-
localization studies with different organelle markers in the endosomal/lysosomal pathway 
(I). The generation of a PAP-deficient mouse also enabled us to study the function/s of PAP 
in vivo. The lack of PAP in this mouse model led to the gradual changes in the mouse prostate 
that finally culminated with the development of prostate adenocarcinoma at the age of 12 
months. Microarray analyses of different tissues that compared the PAP deficient mouse with 
the wild type (WT) mouse revealed changes in genes related to the vesicular trafficking, 
which support our previous results and led us to the conclusion that TMPAP could be 
involved in the regulation of the vesicular trafficking. We also detected the interaction 
between TMPAP and snapin, a SNARE (Soluble NSF Attachment Protein Receptor) 
associated protein, by yeast two-hybrid screening, co-localization and FRET (Förster 
resonance energy transfer) analysis. We concluded that, the disruption of this interaction in 
the PAP-deficient mouse leads to a disturbance in the vesicular transport of the cell and to 
the development of prostate adenocarcinoma in the PAP-deficient mouse prostate (II). 
Furthermore, we showed that the PAP-deficient mice present multiple behavioral and 
neurochemical alterations including increased size of brain lateral ventricles, 
hyperdopaminergic deregulation, and altered GABAergic transmission, symptoms that 
indicate that PAP also disturbes the normal function of the central nervous system (III). 
Snapin protein in the brain has been described as a protein important for the vesicular 
transport and for the fusion of vesicles with the plasma membrane, and we observed that the 
lack of PAP in GABAergic neurons leads to a change in the localization of snapin in the 
PAP-deficient mouse (III), which could indicate that as in the prostate a dysregulated 
vesicular trafficking could be the reason for the detected phenotype. 
The discovery of the new TMPAP and its localization in the endosomal/lysosomal 
pathway enabled an understanding of the phenotypic changes that occur in the PAP-deficient 
mouse. We hypothesized that TMPAP regulates vesicular trafficking by interacting with 
snapin, and its deficiency leads to a dysregulation of the endo-/exocytosis cycle, which 
produces the observed alterations in the mouse organs and tissues. The results obtained 
throughout this research project have opened up new lines of research related to PAP 
physiological function, and a deeper understanding of the expression, regulation and function 
of this protein could lead to new clinical applications. 
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1. Review of the literature 
1.1 Biochemical features, protein structure and gene regulation of PAP 
The characterization of phosphatases started in the beginning of the 20th century, 
and the extractions methods used to obtain proteins from tissues gave the incorrect idea that 
phosphatases acted at pH values higher than 8.8. These isolation methods obtained very low 
yields of phosphatase activity and even the total loss of activity. However, important results 
were obtained from these early studies and they made possible the initial classification and 
characterization of the phosphatases based in: their enzymatic activity at different pHs, the 
study of the inhibitory properties of substances such as fluoride or free phosphate, and the 
capability of the phosphatases to dephosphorylate a wide spectrum of substrates including 
glycerophosphate, hexose diphosphate or nucleotides (King. 1932, Kay. 1928, Robison. 
1923).  
In 1938, Gutman & Gutman established the relation between prostate cancer and 
the increased activity levels of acid phosphatases in serum samples (Gutman and Gutman. 
1938), opening the research in the phosphatases field trying to characterize each of them and 
their potential clinical applications. 
1.1.1 Initial biochemical characterization of PAP 
One of the first achievements in the attempt to characterize more accurately the acid 
phosphatase produced in the prostate was the tartrate inhibition described by Abul-Fadl & 
King (Abul-Fadl and King. 1948), and introduced by Fishman & Lerner in 1953 as a clinical 
method for the determination of the specific prostatic acid phosphatase activity levels in 
patient serum samples (Fishman and Lerner. 1953, Fishman, et al. 1953). However, it was 
later shown that other acid phosphatases present in leukocytes were also inhibited by tartrate 
(Li, et al. 1970). In acidic conditions, at least five different acid phosphatase isoenzymes were 
described to be present in tissue extracts by electrophoretic mobility. Lam and co-workers 
reported acid phosphatase isoenzyme 2 to be the most specific acid phosphatase isoenzyme 
for prostate, based in its high level of expression in prostate tissue extracts and its similarities 
to the acid phosphatase present in seminal fluid samples (Lam, et al. 1973). The isoenzyme 
2 presented a molecular mass of about 100 000 Da (Ostrowski and Rybarska. 1965, Lam, et 
al. 1973) and an optimal activity between pH 5.5 and 7.0 (Roy, et al. 1971, Lam, et al. 1973).  
A number of different substrates were tested for PAP in an attempt to improve the 
specificity of the reaction to be used in clinical assays. One of such case was thymolphthalein 
(Roy, et al. 1971), which was later demonstrated not to be specific (Lam, et al. 1973). PAP 
presents a low substrate-specificity in vitro, which allows it to dephosphorylate a broad range 
of different compounds. hPAP is able to dephosphorylate simple synthetic molecules such as 
phenol phosphate and α-naphtylphosphate (Seal, et al. 1966), small biological compounds 
including α-phosphoglycerol, β-phosphoglycerol, phosphotyrosine and phosphoglycine 
(Schwartz, et al. 1953), phosphorylcholine (Serrano, et al. 1977); and also complex biological 
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molecules such as 5?-nucleotides (Vihko. 1978) and proteins phosphorylated in their tyrosine 
(Nguyen, et al. 1990, Lin, et al. 1992), serine or threonine residues (Lee, et al. 1991). 
The transphosphorylation reaction has been also described for and attributed to PAP. 
The transfer reaction catalyzed by PAP showed that donor substrates such as 
phenylphosphate, p-nitrophenylphosphate, propanediol phosphate, or glycerol phosphates 
have the same efficiency for the donation of the phosphate group. This reaction was, 
however, influenced by the acceptor alcohols, which indicated that the best acceptors were 
glycols with their alcohol groups separated by at least one carbon atom (Nigam and Fishman. 
1959, Buchwald, et al. 1984).  
1.1.2 PAP protein structure 
1.1.2.1 Protein characteristics 
Human PAP is a phosphomonoesterase (EC 3.1.3.2), which catalyzes the hydrolysis 
of a phosphate monoester to its alcohol and phosphate. Ostrowski and co-workers showed 
that hPAP is a glycoprotein formed by two subunits with molecular weight of about 50 kDa, 
which can be dissociated into two enzymatically-inactive polypeptides at extreme pHs 
(Luchter-Wasyl and Ostrowski. 1974). In addition, Smith and Whitby indicated that some of 
the PAP heterogeneity observed by starch-gel electrophoresis was due to the differences in 
the sialic acid content of the protein (Smith and Whitby. 1968).  
The isoenzymes isolated from tissue have been usually compared to the one present 
in the seminal plasma that was considered to be homogeneous and specific for the prostate 
(Lam, et al. 1973). However, it has been observed that it is possible to isolate at least two 
PAP isoenzymes from seminal plasma (Lin, et al. 1983, Lee, et al. 1991). The main 
isoenzyme was called PAP-A, and the minor PAP-B. These isoenzymes occur in a ratio of 
9:1, and they can be also isolated from prostatic tissue (Lin, et al. 1983, Lee, et al. 1991, 
Vihko. 1979). Immunological characterization of the isoenzymes showed that PAP-A has a 
total immunological identity with PAP-B. However, PAP-B also holds unique 
immunological determinants, which could be used to distinguish it from PAP-A. Lee and co-
workers showed that the main isoenzyme of PAP in seminal fluid, PAP-A comprises two 
identical polypeptides meanwhile PAP-B was considered to be a heterodimer (Lee, et al. 
1991). 
Brian Hartly proposed the classification of proteolytic enzymes based on the amino 
acid residues that are present in the active-site and are involved in the catalytical process, i.e. 
as a nucleophilic acceptor (Hartley. 1960). Hartley’s basic approach was later followed by 
Van Etten in 1982, who classified phosphatases in similar way. Van Etten described PAP as 
being a histidine acid phosphatase because histidine was essential for the catalytic activity of 
the enzyme (Van Etten. 1982). The possibility of cDNA sequencing of hPAP (Vihko, et al. 
1988) and other well-known acid phosphatases such as human lysosomal acid phosphatase 
(Peters, et al. 1989), rat lysosomal acid phosphatase (Roiko, et al. 1990), and acid 
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phosphatase from Escherichia coli, allowed the comparison of their sequences and the 
establishment of a common and conserved region that characterized these enzymes, the 
conserved motif RHGXRXP (Van Etten, et al. 1991). 
1.1.2.2 Crystal structure  
Protein crystallography is a standard method that can ascertain the three-
dimensional (3D) protein structure. The protein has to be highly pure and homogeneous, keep 
a native structure, retain its activity and be stable for successful protein crystallography. The 
cloning and sequencing of hPAP, which encodes a 386-residue protein including the 5? signal 
peptide of 32 amino acids (Vihko, et al. 1988), allowed the screening of rat prostatic cDNA 
libraries and the searching for the rat PAP (rPAP) DNA sequence (Roiko, et al. 1990). The 
rPAP protein comprises a sequence of 350-amino acids plus a 31-residue-long signal peptide 
and has a 75% identity with the hPAP sequence (Roiko, et al. 1990). The use of recombinant 
techniques and the production of protein in large scale by using baculovirus expression in 
insect cells have allowed the production and isolation of high amounts of pure enzyme to 
carry out crystallographic studies and determine the three-dimensional (3D) structure of the 
protein (Vihko, et al. 1993). 
3D studies showed that the enzyme is formed by two domains, an α/β domain similar 
to the one present in the phosphoglycerate mutase, and an α-helix domain. The α/β domain 
is formed by seven-stranded mixed β-sheet with α-helices on both sides of the β-sheet, and 
during dimerization the structure is extended and forms a disc shape of 14-stranded β-sheets 
(Schneider, et al. 1993). 
The interactions between the third β-strand in the α/β domain of each subunit leads 
to the formation of the dimer. The dimer does not form disulphide bonds between its subunits 
(Luchter-Wasyl and Ostrowski. 1974) but the monomers are held together by hydrophobic 
interactions and possibly hydrogen bonds between the residues pairs Gln37 and His67, Tyr65 
and Asp78 and Asp76 and His112 in the rPAP (Schneider, et al. 1993). In addition, the 
Trp106 residues in each subunit are stacked on top of each other, which also contribute to the 
interaction between monomers and their dimerization (Schneider, et al. 1993). Site-direct 
mutagenesis of the Trp106 and the His112 has shown the importance of these residues in the 
oligomerization of the enzyme (Porvari, et al. 1994). The 3D structure of rPAP reveals that 
the active sites are separated from each other in the dimer (Schneider, et al. 1993), and 
therefore it has been considered that they do not exert cooperation during the enzymatic 
reaction. However, mutations in Trp106 and His112 residues, which are involved in the 
oligomerization of the protein, generated inactive monomers and indicated that the own 
dimerization process might also act as an enzymatic activation mechanism (Porvari, et al. 
1994). Initially, it was considered that PAP followed Michaelis-Menten kinetics, but detailed 
studies have shown that despite the substrate, PAP exhibits positive cooperation and this 
cooperation increases when PAP concentrations increase (Luchter-Wasylewska. 2001). This 
positive cooperation between the active sites could explain why it was not possible to isolate 
active monomers of the protein even by using site-direct mutagenesis (Porvari, et al. 1994), 
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which indicates that the interaction between the monomers leads to conformational changes 
in the active site that subsequently affects the enzyme activity.  
Structural studies showed that the active site of PAP is rather open with an 
accessible cleft, and this feature explains the broad range of structurally different substrates 
that are dephosphorylated by the enzyme (Schneider, et al. 1993, Lindqvist, et al. 1993).  
1.1.2.3 Active site and enzymatic reaction 
The first attempts to determine the amino acid residues present in the active site and 
those residues directly involved with the enzymatic reaction were accomplished by chemical 
modification of the residues. Van Etten and co-authors were thus able to unveil the amino 
acids involved in the enzymatic reaction by using chemical modifications of their residues 
and also by the competitive inhibition with L-(+)-tartrate. Those authors established that 
during the reaction three main requirements should be fulfilled: 1) the presence of a cationic 
group in order to facilitate the orientation and formation of the co-ordinated complex between 
the protein and the phosphate group, 2) the ability to protonate the donor group in order to 
allow the reaction to continue rapidly, and 3) the need for a nucleophilic agent in the reaction 
considering the already known chemical models for phosphate ester hydrolysis (Van Etten. 
1982). The use of chemical modifications and trapping experiments established that arginine 
acted as the cationic group (McTigue and Van Etten. 1978), aspartic acid or glutamic acid as 
the protonating group (Saini and Van Etten. 1979), and histidine as the nucleophilic group 
(McTigue and Van Etten. 1978, Ostrowski and Dziembor-Gryszkiewicz. 1980). These three 
residues were the essential amino acids in the active site, and directly related to the enzymatic 
reaction. 
The elucidation of the groups involved in the enzymatic reaction enabled the 
construction of the mechanistic hypothesis for the reaction. Assays that were performed using 
different oxygen, phosphorus and carbon isotopes elucidated how the reaction proceeds and 
which atoms were directly involved in the reaction (Ostrowski. 1978, Van Etten. 1982). The 
hydrolysis of the phosphate group occurs by nucleophilic attack of the phosphorous atom by 
the nitrogen of a histidine residue in a SN2 reaction (Van Etten. 1982). It was later shown that 
the histidine residue in the conserved motif, RHGXRXP, serves as the nucleophile in the 
formation of the covalent phospho-histidine intermediate (Ostanin, et al. 1992, Lindqvist, et 
al. 1994), and a conserved aspartic acid residue serves as a proton donor to the oxygen atom 
of the phosphoester bond (Lindqvist, et al. 1994).  
The crystallographic studies (Lindqvist, et al. 1993, Schneider, et al. 1993, 
Lindqvist, et al. 1994) and the site-direct mutagenesis (Porvari, et al. 1994) performed in 
rPAP allowed the clear characterization of the amino acid residues involved in the active site 
and their function in each step of the reaction. The residues that form part of the acid 
phosphatase motif RHGXRXP (Van Etten, et al. 1991) in the sequence of rPAP are Arg11, 
His12 and Arg15; but in addition, the residues Arg79, His257 and Asp258 have also been 
identified as conserved amino acid residues present in the active site (Schneider, et al. 1993). 
Mutating the Asp258 by asparagine, serine or alanine shows the lack of activity in the mutant 
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enzyme and its importance in the enzymatic reaction (Porvari, et al. 1994). 
1.1.3 Gene regulation of PAP 
The need for androgen for prostate development and maintenance has clearly been 
shown as indicated in the review by Maker and co-authors (Marker, et al. 2003). Prostate-
Specific Antigen (PSA) and human glandular kallikrein 2 (hK2) expression are also 
important for prostate development and maintenance. The expression of these proteins is 
regulated by the presence of steroid regulatory elements (SRE) in their promoter sequences 
(Riegman, et al. 1991, Murtha, et al. 1993). PAP is also a protein that is secreted mainly by 
the human prostate, therefore comparison between PAP and other prostatic proteins such as 
PSA, hK1 or/and hK2 seemed to be a logical approach to determine if they share similar 
sequences in their respective promoter area, and if they could be regulated in similar ways. 
1.1.3.1 Expression in LNCaP cells 
The first attempts to understand PAP expression and regulation were performed 
using LNCaP cells.  LNCaP cells are derived from a metastasis of prostate cancer in the 
lymph node, and it is a cell line that can respond to androgens and secrete PAP and PSA as 
prostatic markers (Horoszewicz, et al. 1980, Horoszewicz, et al. 1983). However, culturing 
LNCaP cells under different hormonal conditions produced controversial results. Some 
authors showed that androgens in LNCaP cells decreased protein and mRNA levels of PAP 
(Henttu and Vihko. 1992, Henttu, et al. 1992), whereas others concluded that androgens 
increased PAP mRNA levels and secretion (Lin, et al. 1993). Later work has shown that 
differences in cell density could affect the PAP mRNA level and hence its protein production 
and secretion (Lin, et al. 1993). 
1.1.3.2 PAP mRNA levels in prostatic tissue 
The divergence of results using LNCaP cells as a model and the effect of steroids 
on its intrinsic capacity to produce PAP led to the need for alternative approaches to 
understand PAP regulation. Tissue culture assays were designed and performed to determine 
the effect of hormones in normal and cancerous prostatic tissue (Nevalainen, et al. 1993). 
The results clearly showed that androgens play major roles in the maintenance of normal 
prostate tissue and its differentiation, in addition to changing the PSA secretory capacities of 
the tissue (Nevalainen, et al. 1993).  
Three PAP transcripts with clearly different sizes can be isolated in the rat model, a 
long transcript of 4.9 kb and two shorter transcripts of 2.3 kb and 1.5 kb, respectively (Roiko, 
et al. 1990). Porvari and co-authors carried out the analysis of rPAP transcripts in castrated 
rats and androgen supplemented animals to clarify the effect of androgens in the expression 
level of rPAP (Porvari, et al. 1995). They showed that two of the three transcripts responded 
to the manipulation of the androgen levels, and the longest transcript of 4.9 kb was unchanged 
despite the treatment (Porvari, et al. 1995).  
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Studies that used human prostate normal tissue have shown that hPAP mRNA 
expression is regulated by androgens in tissue cultures but this regulation depends on 
androgen concentration (Dulinska, et al. 1997). Further studies with growth factors have 
shown that the expression levels of PAP and PSA in humans differ in their regulation. In 
addition, a synergy between androgens and basic fibroblastic growth factor (bFGF) for PAP 
expression was observed, whereas in the case of PSA the synergistic effect was observed 
between androgens and EGF (Dulinska, et al. 2002). 
The results of these studies combined show that androgens are essential for the 
normal maintenance of the prostatic tissue and that androgen levels can affect the expression 
of the proteins secreted by the prostate.  
1.1.3.3 Promoter analysis 
The clear results obtained for PAP expression in rat and human prostate tissue 
cultures led to the identification of the transcriptional regulatory sequences in the PAP 
promoter region. The comparison between hPAP and rPAP promoter sequences revealed five 
putative SRE sequences. In vitro analysis of these sequences showed that two out of the five 
putative sequences were capable of binding to the androgen receptor (AR), and one of these 
sequences was conserved between hPAP and rPAP (Virkkunen, et al. 1994). Interestingly, 
the conserved steroid response elements (SRE) in the hPAP is located in a similar position (-
178 nt from the transcriptional start site) to the SRE of other prostatic proteins such as human 
kallikrein 2 (hK2) and PSA (-160 and -170 nt respectively) (Shan, et al. 1997). 
An in silico analysis of the PAP promoter showed the presence of sequences with 
the ability to bind many different transcription factors such as AP-1, AP-2, NF-κB, Nkx2.5, 
HNF, cAMP response elements and SRE (Virkkunen, et al. 1994, Zelivianski, et al. 2000). 
However, few of these transcription factor sequences were fully analyzed. Shan and co-
workers showed a differential regulation by steroids of the hPAP transcript from those of 
hPSA and hK2 genes. The promoter construct used in their study covered the region of -
734/+467, and even when it concealed two SRE sequences in the hPAP (-178/-164 and 
+336/+350) (Virkkunen, et al. 1994), the expression of the reporter genes was unchanged in 
the presence of different steroids (Shan, et al. 1997). Analysis of a longer upstream fragment 
-1305/+87 showed an increased expression level of the reporter gene in cells grown under 
reduced steroid conditions, which was inversely correlated with cell growth (Zelivianski, et 
al. 1998). This result indicated that steroids do affect the expression levels of the protein. 
However, the use of different sizes and regions of the promoter (upstream regions of the 
promoter and intronic segments) led to a lack of consensus in the specific function of those 
sequences.  
The characterization of upstream areas of the PAP promoter (3kb upstream of the 
initial codon) led to the identification of negative and positive elements in the gene regulation 
(Zelivianski, et al. 2000). The transfection of different sequences of the promoter that 
preceded the chloramphenicol acetyl transferase (CAT) gene (as a reporter gene) indicated 
that androgens produced a differential activation of the reporter gene. The fragment of -
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779/+87 did not show changes in CAT activity in absence of steroids, the -1305/+87 promoter 
fragment showed a clear up-regulation of the CAT activity under the same conditions 
(Zelivianski, et al. 2000). The transfection of a construct that compared the two fragments 
clearly showed that the sequence between -1305/-779 nt in the PAP promoter region 
contained a cis-active element that can exert its function in prostate derived cells but not in 
non-prostatic cells, which indicates a cell-specific transcriptional activation (Zelivianski, et 
al. 2000, Zelivianski, et al. 2002, Zelivianski, et al. 2004). Footprinting analysis of the cis-
active element identified a novel binding site for the NF-κB transcription factor (Zelivianski, 
et al. 2004). 
Two different constructs that contained the PAP promoter sequence plus and 
intronic area (-734/+467 nt), or the PAP promoter sequence alone (-734/+50 nt) placed in 
front of the CAT reporter gene were expressed in transgenic mice. From these two sequences 
only the one that carried the intronic segment was specifically expressed in prostate 
indicating that a prostate-specific sequence was present in this intronic region. An analysis 
of the rat probasin promoter revealed the presence of a 12 nt sequence GAAAATATGATA, 
which was protected in a DNaseI footprinting assay using prostate cell nuclear extract 
(Patrikainen, et al. 1999). Five homologous sequences to the probasin sequence were present 
in the PAP promoter (-734/+467 nt) but only two of these sequences were protected by 
nuclear extracts of prostate cells in a footprinting assay (Shan, et al. 2003). The analysis of 
these sequences indicated that they regulate the expression of the protein in response to 
androgens, but it was suggested that they can act as positive or negative regulators that 
depended on the androgen concentration (Shan, et al. 2005).  
1.2 Anatomical distribution of PAP 
Several researchers in the early part of the 20th century were able to show the 
catalytic activity of tissue homogenates or tissue extracts to dephosphorylate phosphoesters 
in vitro, which indicated the presence of enzymes that could carry out this reaction (Plimmer. 
1913, Kay. 1928). However, it was not until the late 1940s and early 1950s that these enzymes 
were successfully characterized by their chemical properties (Barger. 1947). 
1.2.1 PAP in the prostate 
The major production of PAP in human takes place in the prostate gland, and this 
enzyme inherit its name from this organ. Kutscher and Wolbergs in 1935 were the first to 
describe the acid rich phosphatase content of normal prostate tissue (Kutscher and Wolbergs. 
1935), these observations were later confirmed by Gutman and Gutman (Gutman and 
Gutman. 1938). PAP is released by the prostate gland into the semen with high activity in 
humans (Rui, et al. 1986, Ronnberg, et al. 1981). However, in mouse the main expression of 
the protein is not by the prostate but is found in the submandibular salivary glands, an organ 
that in the mouse displays sexual dimorphism during development (Araujo, et al. 2014).  
Despite the differences between the human and the mouse prostate, mouse models 
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have been used for the study of prostate cancer due to the low frequency of both benign and 
malignant prostatic diseases in the mouse. However, there are important anatomical 
differences between the human and the mouse prostate that have to be considered for a more 
reliable understanding of the results. 
1.2.1.1 The Human prostate 
The human prostate is a unilobular structure that is anatomically located between 
the bladder and the penis, and is transected by the urethra. The human prostate is 
histologically and anatomically heterogeneous, where four basic anatomical regions can be 
described using the urethra as a reference point. The four zones are the peripheral zone, which 
constitutes about the 70% of the gland, the central zone, the transition zone and the 
fibromuscular zone (Figure 1) (McNeal. 1981). These four zones show marked histological 
differences, which could imply biological or functional differences, and they also exhibit a 
marked differential predisposition to the prostate pathologies (Laczko, et al. 2005).    
The central and the peripheral zones can be easily distinguished by using 
histological stains such as haematoxylin and eosin. The peripheral zone shows small and 
round acini that are surrounded by loosely arranged stroma which is in turn formed by smooth 
muscle fibers. In contrast, the central zone has large acini separated by stroma that contain 
densely-packed smooth muscle fibers. The histology of the transition zone is similar to that 
of the peripheral zone (Laczko, et al. 2005). 
In the human prostate, immunohistochemical studies showed that PAP is present in 
the apical portion of the prostatic columnar epithelial cells (Shaw, et al. 1981, Zondervan, et 
al. 1986, Laczko, et al. 2005), however it is absent in the basal cells of the prostatic acini 
Figure 1. Schematic representation of human prostate according to Mc Neal model. 
20 
 
(Zondervan, et al. 1986, Laczko, et al. 2005). Immunoelectron microscopy revealed the 
presence of PAP in secretory vesicles and vacuoles of the prostatic epithelial cells (Mori and 
Wakasugi. 1985, Song, et al. 1985, Zondervan, et al. 1986), the microvilli of these cells (Mori 
and Wakasugi. 1985, Song, et al. 1985) and in lysosomal granules (Warhol and Longtine. 
1985, Zondervan, et al. 1986). No differences in the expression of PAP were observed 
between the three prostatic zones (Laczko, et al. 2005). 
1.2.1.2 The Mouse prostate 
The mouse prostate is not one compact organ as is the case for the human prostate, 
but it consists of four lobules that encircle the urethra. The lobules are named as the anterior 
prostate (AP) and is also known as coagulating glands, dorsal prostate and lateral prostate, 
which are both collectively referred to as the dorso-lateral prostate (DLP) because they share 
the ductal system that empty the lobes into the urethra, and the fourth lobule is the ventral 
prostate (VP) (Figure 2) (Roy-Burman, et al. 2004).   
The mouse prostate presents a thin fibromuscular layer surrounding the gland acini, 
and lose connective tissue that connects them. The prostatic lobes present differences both in 
the epithelial layer that covers the glands and in their secretion. The DLP has simple short 
cylindrical secretory epithelium, which presents few foldings, the nuclei have a central to 
basal location, and the secretion is a homogeneous eosinophilic substance. The AP has a 
Figure 2. Schematic representation of mouse prostatic lobes and its normal histology. 
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cuboidal to columnar epithelium with centrally located nuclei. The epithelium presents many 
folds that project into the lumen of the gland that contains a homogeneous eosinophilic 
secretion. The monolayer epithelium of the VP has columnar cells with basal located nucleus, 
and presents focal folding. Unlike DLP and AP secretion, the secretion of VP is slightly more 
basophilic (Roy-Burman, et al. 2004).  
1.2.2 PAP localization in non-prostatic tissues 
No specific substrates and inhibitors for PAP were discovered in the first 70 years, 
which made it difficult to determine if the acid phosphatase isoenzyme present in the prostate 
was also present in the non-prostatic tissues. The development of specific antibodies against 
the enzyme opened up the possibility to screen non-prostatic tissues that could also express 
PAP. However, the use of polyclonal and monoclonal antibodies led to mixed results.  
Choe and co-authors observed the immunological localization of PAP in a case of 
pancreatic islet carcinoma that had metastasized in the liver, which was suggesting a prostatic 
effect but this was later dismissed by post-mortem pathological investigation (Choe, et al. 
1978). Yam and co-workers in the early 1980’s described the presence of an acid phosphatase 
with antigenic properties similar to PAP in the serum of one patient with neutrophilic 
leukemia. Those authors also found that the enzyme was present in neutrophils of one patient 
with acute granulocytic leukemia, two patients with polycythemia vera with neutrophilia, and 
five normal samples (Yam, et al. 1981). Several studies, on the other hand, described the lack 
of reaction of polyclonal and monoclonal antibodies with non-prostatic tissue that included 
the pancreas, kidneys, and nucleated blood cells (Nadji, et al. 1980, Shaw, et al. 1981, Kuciel, 
et al. 1988). However, the presence of PAP in the Islets of Langerhans has been described in 
different research publications by different research teams (Jobsis, et al. 1981, Haines, et al. 
1989). The presence of PAP was also reported in neuroendocrine pancreatic tumors (Choe, 
et al. 1978, Kaneko, et al. 1995, La Rosa, et al. 2011). These findings led to the conclusion 
that PAP is expressed in these cells but at low levels. 
Proteins with the same biochemical characteristics as PAP and which react with 
PAP antibodies have been described in the placenta (Skinningsrud. 1983), epidermis 
(Makinen. 1985), stromal carcinoids of the ovary (Sidhu and Sanchez. 1993) and human 
endometrial glands (Partanen. 2008). 
Graddis and co-workers performed immunohistochemistry, in situ hybridization and 
quantitative polymerase chain reaction (qPCR) studies in human samples, which showed 
PAP expression in non-prostatic tissues such as the pancreas’ Islets of Langerhans, hair 
follicles, and epidermis; but PAP expression in these tissues was found to be significantly 
lower (one to two orders of magnitude) than in the human prostate (Graddis, et al. 2011). 
A PAP-deficient mouse model developed recently (Vihko, et al. 2005) enabled 
Zylka and collaborators to show that PAP can also be expressed in the dorsal root ganglia 
(DRG), and in the spinal cord of mice. Thiamine monophosphate (TMP) was used by Zylka 
and colleagues as the substrate in an enzymatic reaction, and they demonstrated the 
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dephosphorylation of TMP by PAP. The results showed a dark precipitate stain in the upper 
dorsal horn of WT mice, whereas no precipitate was visualized in the PAP-deficient mice 
samples (Zylka, et al. 2008). The presence of a phosphatase able to dephosphorylate TMP 
under acidic conditions has been used for decades as a marker for primary nociceptive 
neurons (Csillik, et al. 1986), the phosphatase was called thiamine monophosphatase 
(TMPase) based on the substrate name. The assays performed in PAP-deficient mice have 
clearly shown that PAP is indeed the so-called TMPase. TMPase activity was observed in 
small dorsal root ganglia cells and in the plasma membrane of the synaptic glomeruli in the 
substantia gelatinosa Rolandi (Ogawa, et al. 1981), which showed the same localization that 
the fluoride-resistant acid phosphatase that was later described by Nagy and co-authors 
(Nagy, et al. 1982). 
TMPase staining in the brain has been used to characterize the location of the 
phosphatases involved in the metabolism of thiamine (vitamin B1), which is an important 
cofactor for glucose metabolism (Nelson and Cox. 2005). Inomata and Ogawa observed the 
presence of TMPase activity in the brain stem, specifically in the medulla oblongata (Inomata 
and Ogawa. 1981). Research in patients with alcohol-induced cirrhosis showed an increased 
activity of TMPase in the caudate nucleus of alcoholic subjects (Rao and Butterworth. 1995). 
Studies of the brain tissue of Alzheimer’s patients revealed significant decreases activities of 
thiamine phosphate dephosphorylating enzymes, including reduced TMPase activity 
(Heroux, et al. 1996).  
A recent study by Araujo and co-authors showed that PAP is the main phosphatase 
in the submandibular salivary gland of the male mouse, and that at pH 5.6 PAP specifically 
dephosphorylates TMP (Figure 3) (Araujo, et al. 2014).  
PAP is expressed in the granular convoluted tubule (GCT) cells of the 
submandibular salivary gland (Araujo, et al. 2014), which are androgen-dependent cells 
(Treuting and Dintzs. 2012).  
Figure 3. Submandibular salivary gland of WT and PAP-deficient mice stain using TMP histochemistry. TMPase
activity in CST cells is clearly observed in WT mouse, and no activity is present in the PAP-deficient mice
(Unpublished pictures). 
 23 
 
1.3 PAP, interacting proteins and proposed functions 
Despite the long history of PAP in biology and medicine, little is known about 
interacting proteins and the physiological functions of the enzyme. However, a few 
interacting partners have been established and functions have been proposed. 
1.3.1 Regulation of Epidermal Growth Factor 2 (ErbB2) phosphorylation 
Lin and collaborators postulated that a cellular form of PAP regulates the 
phosphorylation status of prostatic cells (Lin, et al. 1992), which can affect cell growth. In 
vitro assays that use radioactive phosphorous labeled proteins have demonstrated the 
phospho-tyrosine phosphatase property of PAP. In addition, PAP that was purified from 
prostate homogenates was found to be more effective dephosphorylating p-Tyr- than p-Ser- 
or p-Thr-proteins. The large amounts of PAP produced in the prostate led to the conclusion 
that PAP is the main phospho-tyrosine phosphatase present in the tissue of the prostate (Li, 
et al. 1984).  
The cloning of a PAP construct in PC-3 cells and the selection of different clones 
conducted to Lin and coworkers to conclude that two different PAP forms exist, which they 
described as a secreted and a cellular form. The secreted PAP, according to Lin and co-
workers, had no apparent effect on the p-Tyr levels of the cell and therefore on cell growth, 
whereas the cellular form of PAP exhibited reduced p-Tyr levels and growth rates in the cells 
(Lin, et al. 1992).  
The same research group showed that the p-Tyr level of a 185 kDa phosphoprotein 
(pp185) was negatively correlated with the PAP expression levels (Lin and Meng. 1996). 
Further studies in this line of research revealed that ErbB2 was the pp185 that had been 
previously observed, and analysis of different subclones of LNCaP cells indicated the 
negative correlation between cellular PAP activity and the p-Tyr level of ErbB2. Therefore, 
those authors concluded that cellular PAP down-regulates cell growth by dephosphorylating 
p-Tyr in ErbB-2 in LNCaP cells (Meng and Lin. 1998). However, the so-called cellular PAP 
has hitherto never been cloned, and no adequate explanation for the presence of PAP in the 
cytoplasm has been given.  
The androgen-responsive behavior of prostate cancer cells was inversely correlated 
with the phosphorylation status of ErbB2, but not with its protein level, which indicated that 
the p-Tyr level was a main player in the proliferation regulated by androgens (Meng, et al. 
2000). More recently, Lin’s group demonstrated an interaction between PAP and ErbB2 by 
using immunoprecipitation methods, and that the cellular PAP dephosphorylates ErbB2 in its 
Tyr (1221/2) site, blocking downstream signals and reducing cell growth (Chuang, et al. 
2010). 
1.3.2 PAP interaction with PSP94 
PSP94 (prostatic secretory protein of 94 amino acids) also known as 
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microseminoprotein beta (MSMB) has been described as a seminal fluid protein of about 
16kDa, and comprises a sequence of 94 amino acids. The serum level of the protein is reduced 
in prostate cancer patients, which indicates its potential value in clinical lab analysis (Dube, 
et al. 1987). A later study showed the specific localization of PSP94 and its mRNA in the 
epithelial cells of the prostate (Brar, et al. 1988). 
Looking for probable interacting partners for PSP94 protein, Anklesaria and 
coworkers used chromatographic separation of seminal plasma. They observed the presence 
of PSP94 in a main fraction and in additional fractions which contained proteins with higher 
molecular weight. The analysis of one of those fractions identified PAP as an interacting 
protein, and the results were confirmed by co-immunoprecipitation (Anklesaria, et al. 2013). 
1.3.3 PAP as an ecto-5'-nucleotidase 
PAP has been found to play an important role in the peripheral and central nervous 
system. Zylka and co-workers demonstrated that PAP was expressed by nociceptive neurons 
in the DRG in mice and were able to dephosphorylate extracellular adenosine monophosphate 
(AMP) to adenosine, which exerted an anti-nociceptive effect via the binding of adenosine 
to the A1-adenosine receptors in the DRG. The same group also demonstrated that the 
intraspinal administration of PAP has potent antinociceptive, antihyperalgesic, and 
antiallodynic effects (Zylka, et al. 2008, Sowa, et al. 2009).  
The ecto-5'-nucleotidase activity of PAP has also been associated with the 
perception of sweet taste. Adenosine is produced in presynaptic cells of the taste buds during 
taste stimulation by the action of the ecto-5'-nucleotidases, NT5E and PAP. The adenosine is 
able to activate Adora2b receptor, which is related to the sweet taste receptor subunit, Tas1r2. 
Moreover, PAP has also been detected in the von Ebner glands (Dando, et al. 2012) a type of 
serous salivary gland that secretes lingual lipase and proteins thought to play a role in the 
taste process (Hand. 2007). 
The analysis of single and double knockout animals allowed the detection of lower 
5'-nucleotidase/AMPase activity in splenocytes and lymphocytes of PAP-deficient mice 
compared to WTs, and to changes in the amount of CD4(+)/CD25(+)/FoxP3 (+) regulatory 
T cells in the thymus. Furthermore, the CD73/PAP double knockout mice showed lower 
percentages of CD4(+) cells in the spleen, regulatory T cells in lymph nodes and the thymus, 
and decreased levels of CD4(+) and CD8(+) cells in the blood. All these findings combined 
suggest a synergistic effect between CD73 and PAP in the immune system (Yegutkin, et al. 
2014). 
1.4 PAP and diseases 
The literature on PAP has been mainly related to two important diseases, namely: 
prostate cancer and Human Immunodeficiency Virus (HIV) infection. The importance in the 
association between PAP and prostate cancer has recently reemerged due to the use of PAP 
as an antigen in immunotherapies for the treatment of prostate cancer.   
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The presence of amyloid fibrils in the seminal fluid formed from PAP-derived 
peptides enhanced HIV infection (Münch, et al. 2007). These observations have opened new 
lines of research about PAP physiology. However, only scant information about the 
formation of these fibrils in vivo and their real physiological function is available. 
1.4.1 PAP in prostate cancer 
Gutman & Gutman were the first to describe the association between PAP activity 
in serum and prostate cancer (Gutman and Gutman. 1938). The authors concluded that 
measurements of acid phosphatase activity in serum samples could be used as a diagnostic 
tool for prostate adenocarcinoma (Gutman and Gutman. 1938).  
The decades that followed the observations of Gutman & Gutman focused on the 
use of PAP as a prostate cancer biomarker. In addition to the lack of specific substrates and 
inhibitors for PAP, the great instability of this protein’s catalytic activity led to the need for 
new methods for its determination. Highly purified PAP allowed animal immunization and 
polyclonal antibody production (Vihko, et al. 1978, Vihko. 1978), this facilitated the 
development of immunological methods that were five times more sensitive than the classical 
biochemical PAP determinations (Murphy, et al. 1978, Vihko, et al. 1982). The use of 
radioisotopes permitted the generation of radioimmunoassays and the use of antibodies, 
which improved the sensitivity in the PAP assays. However, the first radioimmunoassays 
were time consuming, and also the instability of the radio labeled antigen was a major pitfall 
(Vihko, et al. 1978, Choe, et al. 1978, Murphy, et al. 1978). Another method developed for 
PAP detection was the counterimmunoelectrophoresis. This method was slightly less 
sensitive than the radioimmunoassay but did not require radio-labeled antigen and it was also 
less time consuming than the radioimmunoassay approach (Foti, et al. 1978).  
The immunological methods increased the sensitivity (Lee, et al. 1978) and 
specificity (Höyhtyä, et al. 1987) of PAP measurements, which allowed an even better 
classification of the different stages of prostate cancer (Murphy, et al. 1978). However, the 
inability of PAP to detect earlier stages of prostatic disease was its major limitation.  
The development of a second prostate marker, prostate-specific antigen (PSA) 
(Nadji, et al. 1981), and its capability to recognize earlier stages of prostatic disease led to it 
replacing PAP in serological measurements (Shih, et al. 1994, Lange and Winfield. 1987). 
PSA screening has also played a major role in reducing the number of patients with metastatic 
disease (Etzioni, et al. 2008). However, the PSA test as screening tool has also led to the 
overtreatment of indolent disease (Cooperberg, et al. 2007). It is clear that the screening of 
just one tumor marker is not enough for prostate cancer treatment and management; therefore 
several different approaches are required to ensure both a proper diagnosis of the disease and 
also an accurate evaluation and prognosis of prostate cancer after treatment. 
It has recently been claimed that PAP could be of significant prognostic value for 
patients with stage T1–T3 prostate carcinoma and those who are undergoing radiotherapy 
(Taira, et al. 2007). PAP was found to be the strongest predictor of biochemical failure in a 
26 
 
multivariate Cox proportional hazards analysis assay (Dattoli, et al. 2003). 
In 2010, the U.S. Food and Drug Administration (FDA) approved the first 
immunotherapy/vaccine for the treatment of asymptomatic metastatic hormonal-resistant 
prostate cancer using PAP as the antigen (Sipuleucel-T or Provenge) (Traynor. 2010). This 
therapy is based in the concept of “cancer immune-editing”. Theoretically there are three 
stages in the immune response to cancer cells, which are: the elimination, equilibrium and 
escape of cancer cells from the immune system (Dunn, et al. 2004). One way that tumor cells 
avoid the immune system is by using a defective antigen presentation (Rajarubendra, et al. 
2011). This can be countered by the Sipuleucel-T immunotherapy to stimulate the patient 
immune system to enable it to recognize those cells that have previously escaped its attack. 
The Sipuleucel-T approach is based on the isolation of the patient's own antigen-presenting 
cells (dendritic cells, DC), which are then activated ex vivo using a recombinant fusion 
protein between PAP (antigen) and the granulocyte macrophage colony-stimulating factor 
(GM-CSF) to facilitate the stimulation of the immune cell response. The patient’s DCs are 
then re-infused back into the patient to induce the activation of the patient’s cytotoxic T 
lymphocytes in vivo, which allows the recognition and destruction of the prostate cancer cells 
(Rini. 2002, Kantoff, et al. 2010, Dendreon. 2006, So-Rosillo and Small. 2006). Despite the 
benefits of survival achieved by the treatment, one of the main criticisms of this treatment 
approach is related to the comparison designs used in the clinical trials. The critique rises 
since in addition to the placebo and the fusion protein group (PAP:GM-CSF), a third control 
group where DCs treated with GM-CSF should have also been included to evaluate the 
patient response to GM-CSG by itself (Longo. 2010). Furthermore, no correlation has been 
shown between the improvement in survival of the Sipuleucel-T therapy and a measurable 
antitumor effect, such as tumor sizes or serum biomarkers levels (Longo. 2010, Madan, et al. 
2013). 
1.4.2 Amyloid fibril formation and viral infection 
Human Immunodeficiency Virus (HIV) is considered to have a low infectious 
capability, which is mainly due to its inability to attach to the host cell (Eckert and Kim. 
2001). However, it has been shown in vitro that semen can facilitate the transmission of HIV 
(Münch, et al. 2007). Therefore, a new hypothesis has been postulated that considers that 
factors present in the seminal fluid could enhance the viral transmission. Thus, Münch and 
co-workers screened for peptides and small proteins present in the seminal fluid in an attempt 
to identify the factors involved in the enhancement of HIV transmission efficiency. They 
found a fraction that clearly increases HIV infection ability and by using mass spectroscopy 
they identified that all the peptides present were proteolytic fragments of PAP, with one 
predominant peptide that comprises the amino acid residues 248 to 286 of the PAP sequence. 
In addition, the authors have also showed that fresh solutions of the peptides do not have any 
effect on HIV infection rates. However, the aging of the peptide solution did indeed lead to 
the production of an insoluble precipitate capable of enhancing HIV infection. Analysis of 
the precipitate revealed amyloid fibrils named, Semen-derived Enhancer of Viral Infection 
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(SEVI) (Münch, et al. 2007). 
The presence of amyloid fibrils is also observed under normal conditions in human 
seminal plasma (Usmani, et al. 2014), and it has been shown that the SEVI structures do not 
just enhance the infectious ability of HIV per se but also facilitate the infectiousness of other 
retroviruses that have different envelope proteins (Wurm, et al. 2010). Furthermore, SEVI 
structures significantly increase xenotropic murine leukemia virus-related virus (XMRV) 
infections of primary prostatic epithelial and stromal cells. This virus has been associated 
with prostate cancer and may play a role in its tumorigenesis (Hong, et al. 2009). SEVI fibrils 
are able to bind to Gram-positive and also to Gram-negative bacteria, which leads to bacterial 
aggregation and increasing phagocytosis by macrophages. These actions have been proposed 
to be the physiological functions of SEVI fibrils in seminal fluid (Easterhoff, et al. 2013). 
Even when there is a clear effect of SEVI on HIV transmission, no pathway has 
been described for the formation of SEVI in vivo and no protease has been identified in the 
formation of the PAP peptides. It has been observed that amyloid fibrils are not just formed 
by PAP peptides but also by other proteins in the seminal fluid, such as the seminogelins, 
which can be cleaved and their peptides can also form fibril structures that facilitate HIV 
infection (Roan, et al. 2011, Roan, et al. 2014). Remarkably, semens from patients with 
ejaculatory duct obstruction (EDO) lack the factors that enhance HIV infection (Roan, et al. 
2011). The duct obstruction prevents the release of the seminal vesicles content into the 
ejaculate, and the SEVI fibril content is thereby also reduced, meanwhile increased amounts 
of full-length PAP protein can be observed in the ejaculates of these EDO patients. Therefore, 
it is suspected that the protease activity responsible for the cleavage of PAP in peptides is 
produced by a peptidase present in the seminal vesicle fluid (Roan, et al. 2011).  
1.5 Protein synthesis and vesicular trafficking 
1.5.1 Protein synthesis 
The proteins that are destined to be secreted or transported to other organelles are 
synthesized by ribosomes that are attached to the endoplasmic reticulum (ER). Moreover, the 
translocation of these proteins into the ER is the first step in their route to their final 
destination (Ghaemmaghami, et al. 2003). A hydrophobic N-terminal sequence that is formed 
by approximately 20 to 30 amino acidic residues acts as signal peptide (Hegde and Bernstein. 
2006) and produces an arrest in the protein synthesis, and the recruitment of a 
ribonucleoprotein complex known as the signal recognition particle (SRP) (Keenan, et al. 
2001, Saraogi and Shan. 2011, Wild, et al. 2004). The SRP interacts with its receptor in the 
membrane of the ER, which mediates the anchoring of the ribosomal complex to the ER and 
the interaction of the hydrophobic sequence with the Sec61 complex (translocon), then the 
SRP and SRP receptors are released and the translation is re-started, which leads to the 
insertion of the growing peptide into the translocation pore of the ER (Osborne, et al. 2005, 
Robson and Collinson. 2006). During the synthesis and translocation of the protein, the signal 
peptide is removed by peptidase activity (Stroud and Walter. 1999), which leads to the 
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generation of a secretory protein. The presence of a second hydrophobic segment acts as a 
stop-transfer signal to release the ribosomal complex from the translocon, which leads to the 
insertion of the hydrophobic domain into the ER membrane thus yielding a type I protein 
(amino-terminus in the lumen of the ER and carboxyl-terminus in the cytoplasmic side) 
(Katz, et al. 1977, Guan and Rose. 1984, Pitonzo, et al. 2009). It seems that the presence of 
alternated hydrophobic sequences in multiple-pass proteins mediates the binding of the 
ribosomal complex to the translocon and its subsequent release when these sequences are 
translated (Pitonzo, et al. 2009). An internal location of the hydrophobic signal can lead to a 
single-pass transmembrane protein with two different orientations, which produces a type II 
protein that has its amino terminus facing the cytoplasmic side (Lipp and Dobberstein. 1986) 
or a type III protein with its amino terminus facing the lumen of the ER. 
1.5.2 Vesicular trafficking 
The proteins produced in the ER are then recruited in vesicles and transported to 
their final destination. The vesicular trafficking in the cells is basically formed by two 
pathways that share common features, the exocytosis/secretion, and the endocytosis 
pathways. These processes are interconnected and the plasma membrane homeostasis 
depends on the equilibrium and regulation of them (Scita, et al. 2013). Changes in the 
secretory process or in the endocytic mechanisms in addition to the proteins involved in these 
pathways can lead to cell dysregulation and disease (Abderrahmani, et al. 2006, Gitler, et al. 
2008, Jenkins, et al. 2007, Cheng, et al. 2004).  
A precise vesicular trafficking between the compartments is essential to fulfill the 
requirements for a proper exocytosis and endocytosis. The same events are required 
independently of the compartments involved from the donor membrane where the vesicle is 
formed, to the acceptor membrane where the vesicle fuse, which are: 1) vesicle formation 
and cargo selection, 2) transport to the acceptor membrane, 3) selection of the target 
membrane (tethering/docking), and 4) fusion of the vesicle and content released (Figure  4) 
(Schmid. 2004, Hutagalung and Novick. 2011).  
1.5.2.1 Vesicle formation and cargo selection 
The formation of vesicles requires the presence of a GTPase from the ARF/SAR 
family, the cargo to be transported and the proteins for its selection, the recruitment of coat 
proteins (which will interact with the GTPase stabilizing the membrane and the growing of 
the vesicle), and the presence of the SNARE proteins (Spang. 2008).  
The best characterized coat proteins are COP II (transport from ER to the cis-Golgi), 
COP I (retrograde transport from the cis-Golgi to the ER) and clathrin (vesicular trafficking 
between the trans-Golgi and the plasma membrane, or from the plasma membrane to the 
endosomes). In addition, the presence of receptors and/or adaptor proteins facilitates the 
interaction between the coat proteins and the vesicular cargo (Gorelick and Shugrue. 2001).  
On the other hand, the interaction of clathrin with distinct adaptor proteins allows 
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this coat protein to be involved in two opposite processes: exocytosis and endocytosis (Spang. 
2008).  The cargo selection for the clathrin-coated vesicles is mediated by clathrin-associated 
protein complexes or adaptor complexes (AP1-4). These adaptor complexes mainly 
recognize two different sorting motifs: 1) a tyrosine-based sequence YxxΦ where Y is 
tyrosine, x is any amino acid residue and Φ is an bulky hydrophobic amino acid residue 
(Ohno, et al. 1995); and 2) a di-leucine sorting motifs [DE]xxxL[LI] where again x is any 
amino acid residue (Bonifacino and Traub. 2003). Three of the adaptor complexes (AP1, 
AP3, and AP4) are involved in the sorting of transmembrane proteins from the trans-Golgi 
network to their final destination. Meanwhile, AP2 is the main adaptor involved in the 
endocytosis (Guo, et al. 2014). Remarkably, the same tyrosine base sequence, YxxΦ, allows 
the localization of a transmembrane protein to the plasma membrane by interaction with AP1 
and also its endocytosis by interacting with AP2 (Ohno, et al. 1995). Further studies have 
also shown that not simply the tyrosine motif alone but also its position and the amino acid 
residues surrounding it are important determinants for the efficiency of the interaction with 
the adaptor complexes (Ohno, et al. 1996). 
1.5.2.2 Vesicle transport to the acceptor membrane 
Rab proteins have been associated with different steps in the vesicular trafficking 
and they are key players in the vesicular transport and delivery (Hutagalung and Novick. 
2011). These proteins are generally formed by a GTPase domain, and a hypervariable region 
Figure  4. Schematic representation of the vesicular trafficking between donor and acceptor membrane, and 
some of the proteins involved in the process. SNARE, Soluble NSF Attachment Protein Receptor; Rab, Ras-
related in brain.  
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followed by CAAX boxes in which the geranylgeranyl moieties are covalently attached and 
which facilitate the regulated insertion of the Rabs to the membranes (Pfeffer. 2005). Rab 
proteins cycle between the compartments in their active (bound to GTP) or inactive (bound 
to GDP) forms, which enable the interaction with the GTPase-activating protein (GAP) or 
the GTP exchange factor (GEF) in each case (Hutagalung and Novick. 2011).  A clearly 
described function of Rab proteins is the transport of vesicles along cytoskeletal structures 
as in the case of Rab27a, which interacts with MYO5A and enables the movement of 
melanosomes towards the plasma membrane (Bahadoran, et al. 2001). 
1.5.2.3 Selection of the target membrane  
A third function of Rab proteins is the vesicle docking and tethering that occurs by 
the interaction with the tethering factors of the target membrane. Assays performed in Ashen 
mice showed that Rab27a mediates the tight docking of insulin granules onto the plasma 
membrane during glucose stimulation (Kasai, et al. 2005). In addition, the deficiency of the 
Rab27a effector granuphilin significantly reduce the number of insulin granules that are 
docked to the plasma membrane. In addition, a mutant granuphilin which presents a defective 
binding to syntaxin-1a also fails to restore the number of docking vesicles in the plasma 
membrane (Gomi, et al. 2005). 
1.5.2.4 Fusion process 
The process of fusion is carried out by the interaction of soluble N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE) proteins located in the vesicle (v-
SNARE) and in the target membrane (t-SNARE). The complex is formed by one v-SNARE 
and three t-SNARES, which interact to form a complex comprising four-α-helices in a 
quaternary structure that provides the energy required for the fusion (Kasai, et al. 2012). The 
classification of v- and t-SNAREs have fallen into disuse because this classification does not 
take into consideration the vesicular transport events such as fusion between same types of 
vesicles (homotypic fusion) where it is not possible to differentiate between the vesicle and 
the target membrane. Therefore, the classification process of SNAREs is now based on the 
amino acid contribution to the zero ionic layer of the SNARE complex. If the SNARE protein 
contributes an arginine (R) residue is then classified as R-SNARE, whereas if the SNARE 
contributes a glutamine (Q) residue, it is named Q-SNARE (Fasshauer, et al. 1998).  
The vesicular traffic has been extensively studied in the neuronal cells and the 
SNARE proteins described in these cells have been generally called neuronal SNARE, 
between them synaptobrevin/VAMP (R-SNARE), syntaxin I and SNAP25 (Q-SNARE) can 
be differentiated. However, homologous SNAREs have been also described in non-neural 
cells and tissues, a finding which suggests that all forms of vesicle trafficking share common 
basic principles (Lin and Scheller. 2000). 
Exocytosis is carried out in a constitutive manner or is triggered by an external 
stimulus (Gumbiner and Kelly. 1982). Regardless of the mechanism used for secretion, the 
same SNARE proteins are involved and they are the minimal cell requirement for membrane 
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fusion (Weber, et al. 1998). The binding of additional proteins to the complex and its 
structural configuration are able to regulate the different types of secretion in the cell in 
addition to their kinetics (Kasai, et al. 2012). For instance, the studies performed on ultrafast 
exocytosis of synaptic vesicles found that in addition to SNAREs, several interacting proteins 
regulate and modulate the fusion process. The deficiency or mutation of any of these 
interacting proteins can lead to the complete abolition of the synaptic vesicle release or to 
impair the exocytic process (Nonet, et al. 1993, Verhage, et al. 2000, Chae, et al. 2004, Pan, 
et al. 2009). These accessory proteins exert different functions in the SNARE complex and 
the fusion process, some are calcium sensors such as synaptotagmins (Bai, et al. 2004) and 
Doc2 (Yao, et al. 2011), others are involved in the dissociation of the SNARE complex for 
example NSF and SNAPs (Hohl, et al. 1998, Kuner, et al. 2008), whereas yet others are 
believed to have a regulatory effect as it is the case of complexin (Xue, et al. 2007), tomosyn 
(Yu, et al. 2014) and snapin (Pan, et al. 2009). However, the purposes of many proteins 
involved in secretion have not yet been fully determined, and the chain of events that lead to 
the different exocytosis process is still unknown. 
1.5.3 Neurotransmitter secretion 
One of the most studied processes in vesicular traffic is the exocytosis of 
neurotransmitters. The release of synaptic vesicles can be carried out by four different forms 
of exocytosis: ultrafast, asynchronous, tonic and spontaneous (Kasai, et al. 2012). Each type 
of exocytosis has its own characteristics, and some of them are summarized in Table 1.  
Synapses can be divided and classified in different ways depending on how the 
stimulus is transferred (electrical or chemical), in the change of membrane potential in the 
postsynaptic neuron (excitatory or inhibitory), in the location of the axon terminal in the 
postsynaptic cell (axodendritic, axosomatic, axoaxonic or dendrodendritic), or in the 
Table 1. Exocytosis of synaptic vesicles 
Type of 
Exocytosis 
Time Pool of vesicles Additional requirements SNARE 
configuration 
Ultrafast < 1 ms Docked vesicles 
RRP 
? Active zone 
? Vesicles close to voltage-gated 
channels 
? Rapid increases in Ca2+ 
Preassemble 
Asynchronous 100 ms Docked vesicles 
RRP 
Rapid increases in Ca2+ Preassemble 
Tonic 2 s RP Sustained increase in Ca2+ Not assemble 
Spontaneous >1000 s ResP Constantly stimulated by resting 
levels of Ca2+ 
Not assemble 
 Type of vesicles pool: RRP, readily releasable pool; RP, recycling pool; ResP, Reserved pool (Kasai et al., 2012). 
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appearance of their pre- and postsynaptic membranes (asymmetrical synapse also called Type 
I synapse, or symmetrical synapse also known as Type II synapse). Interestingly, some of 
these classifications include a functional relation between them. In the case of type I 
synapses, these are usually excitatory and interact with the dendrites (axodendritic), whereas, 
type II synapses are usually inhibitory and they reach the soma of the neuron (axosomatic) 
(Silverthorn. 2013, Bear, et al. 2001).  
Synapses produce local changes in the membrane potential of the postsynaptic 
neuron, these input signals produce a graded potential whose amplitude is proportional to the 
strength of the signal, and the sum of all the graded potential reaching the trigger zone that is 
located in the axon hillock defines the likelihood of a neuron to fire an action potential 
(Silverthorn. 2013, Bear, et al. 2001). 
Neurotransmitters are essential for chemical synapses, and the binding of the 
neurotransmitter to its receptor in the postsynaptic membrane leads to the opening of ion 
channels that produce a local effect in the polarization of the membrane. The ions that flow 
through the membrane, also determine the depolarization or hyperpolarization of a 
membrane. Membrane polarization increases the probability of firing an action potential in 
the postsynaptic neuron because it brings the membrane potential closer to the firing 
threshold. Therefore, this effect is said to be excitatory and produces an excitatory 
postsynaptic potential (EPSP). However, if the membrane is hyperpolarized, a reduction in 
the probability of firing an action potential occurs that produces an inhibitory postsynaptic 
potential (IPSP) (Silverthorn. 2013, Bear, et al. 2001). 
The neurotransmitters involved in the synaptic transmission are classified as amino 
acids (e.g. glutamate, glycine, and γ-amino butyric acid-GABA), amines (e.g. dopamine, 
serotonin, and acetylcholine) or peptides (e.g. neuropeptide Y and somatostatin). Classical 
examples of excitatory and inhibitory synapses are those that release neurotransmitters such 
as glutamate and GABA respectively (Kuzirian and Paradis. 2011). 
GABAergic and glutamatergic synapses exert their function through the action of 
two different types of receptors, the ionotropic and the metabotropic receptors. Ionotropic 
receptors include ion channels that allow the flow of different ions e.g. the chloride ion (Cl-) 
flow is produced as result of the binding of GABA to its receptor, whereas calcium ion (Ca2+) 
or sodium ion (Na+) can be transported across the membrane by glutamate binding to the 
respective receptor, an action which generates a change in membrane polarity (Ben-Ari, et 
al. 2007, Niciu, et al. 2012). On the other hand, metabotropic receptors belongs to the family 
of G-protein couple receptors, and the binding of the ligand causes the activation of G 
proteins and the downstream inhibition or stimulation of second messenger transmission 
(Kim, et al. 2008, Chalifoux and Carter. 2011, Chalifoux and Carter. 2011).  
It is considered that inhibitory synapses play important roles in the modulation of 
the firing of an action potential (Cobb, et al. 1995, Miles and Wong. 1984), which modifies 
the membrane potential and prevents it from exceeding the threshold (Buhl, et al. 1994, Miles 
and Wong. 1987), or affecting the strength of the synaptic transmission (Davies, et al. 1991).  
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1.5.4 PAP secretion 
 The secretory nature of PAP has been well documented. The presence of a signal 
peptide was first suggested by Paradis and collaborators when they analyzed poly(A)RNA 
and performed in vitro translation in rabbit reticulocytes (Paradis, et al. 1987). The sequence 
analyses of PAP transcripts showed the presence of a signal peptide of about 32 amino acid 
residues (Vihko, et al. 1988), which is conserved in mammals (Roiko, et al. 1990). In 
addition, the screening of the Ensembl databases shows information on nine different 
transcripts present in the database, from which just five lead to protein coding sequences. 
Four out of the five transcripts conserve the signal peptide, and the fifth sequence is a putative 
protein code that lacks the signal peptide and also the acid phosphatase domain (Table 2).  
 Zylka and co-workers demonstrated the importance of the signal peptide in PAP 
and its vesicular trafficking to the plasma membrane for the antinociceptive activity of this 
enzyme in the DRG. They built a construct that lacked the signal peptide of hPAP and 
expressed it in Pichia pastoris, and showed that the product of this construct is not detectable 
by Western blotting (Hurt, et al. 2012).  
Little is known about the secretory mechanism of PAP and the proteins involved in 
its transport between the ER and the plasma membrane. It has been shown that the addition 
of androgens to prostatic tissues clearly enhances the secretion of PAP (section 1.1.3.2.). Lin 
and co-workers reported that the activation of PKC (protein kinase C) leads to the increased 
secretion of PAP (Lin, et al. 2001). Those authors used the PKC activator 12-o-tetradecanoyl-
phorbol-13-acetate (TPA) and demonstrated an increased secretion of PAP that was TPA 
dose-dependent, though no increased expression of the protein was observed during the 
Table 2. PAP transcripts present in Ensembl database 
Name Transcript ID bp Protein Biotype UniProt RefSeq 
ACPP-001 ENST00000336375 3125 386aa  Protein coding P15309 NM_001099  
NP_001090  
ACPP-002 ENST00000475741 1242 353aa  Protein coding P15309 NP_001278966  
ACPP-003 ENST00000351273 1783 418aa  Protein coding P15309 
NM_001134194  
NP_001127666  
ACPP-004 ENST00000495911 584 165aa  Protein coding E9PFE6 - 
ACPP-005 ENST00000483689 561 No protein  Retained intron - - 
ACPP-006 ENST00000489084 563 No protein  Processed transcript - - 
ACPP-007 ENST00000493235 555 No protein  Processed transcript - - 
ACPP-008 ENST00000512463 581 No protein  Retained intron - - 
ACPP-009 ENST00000507647 496 99aa  Protein coding H0Y8T3 - 
Protein coding          Putative protein coding        Non-coding sequence 
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working period. The effect of PKC in PAP secretion was confirmed by using calcium 
ionophore A23187, which produced an increase in intracellular Ca2+ levels that led to the 
activation of PKC. A 50nM solution of 5α-dihydrotestosterone (DHT) also increased PAP 
secretion but less effectively than TPA. Remarkably, PAP secretion was blocked by the 
action of PKC inhibitors in cells activated with TPA or DHT. These results were thought to 
indicate that the effect of DHT in PAP released is mediated via PKC activation (Lin, et al. 
2001).  
  In an effort to clarify the mechanisms behind PAP secretion, Johnson and 
collaborators studied the proteins involved in the last steps of secretion and found that 
secretion of PAP is affected by androgens. Those authors also showed that the interaction 
between Rab27a and its effector JFC1/Slp1 (synaptotagmin-like protein 1) regulates the 
secretion of PAP, and mutations in the lipid-binding domain of JFC1 (C2A) affect the 
docking of vesicles and the secretion of PAP (Johnson, et al. 2005). In addition, they found 
that overexpression of the C2A domain produced an inhibition in the PAP secretion due to 
competition between the JFC1 wild type and the C2A domain by the phosphatidylinositol 
(3,4,5)-trisphosphate (PIP3) that was present in the plasma membrane. However, the 
overexpression of the C2A domain did not affect the PSA secretion in the cells. Those 
author’s results suggested that the pathway that regulates PAP secretion differs from that one 
of PSA secretion and could indicate that PAP and PSA are located in different vesicle subsets 
(Johnson, et al. 2005). Co-localization studies with LAMP2 (marker for lysosomes), EEA1 
(marker of early endosomes) and VAMP2 (v-SNARE protein) clearly showed that both PAP 
and PSA co-localized with VAMP2, which is necessary for the formation of the SNARE 
complex during the vesicular fusion, but only PAP co-localized with both LAMP2 and EEA1 
(Johnson, et al. 2005). JFC1 was found to bind to PIP3 via its C2A domain (McAdara 
Berkowitz, et al. 2001), which is the product of PI3K, and the inhibition of PI3K by 
LY294002 showed a drastic reduction of PAP and PSA secretion stimulated by androgens. 
However, the PAP secretion was more affected than PSA secretion (Johnson, et al. 2005).  
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2. Aims of the study 
The overall aim of this thesis work was to reveal physiological functions of PAP in 
the body and answer the following more specific scientific questions: 
? Is PAP prostate specific? 
? In which normal tissues is PAP expressed? 
? Is there just one isoform of PAP? 
? What is the distribution of PAP in the cells? 
? Which are the proteins that co-localize with PAP? 
? Does PAP interact with other proteins? 
? What is/are the effect/s of PAP deficiency in the mouse? 
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3. Materials and Methods 
3.1 Antibodies and serums (Articles I, II and III) 
Mouse monoclonal anti-lysosomal associated membrane protein 2 antibody (anti-
LAMP2) was developed by J.T. August and J.E.K. Hildreth (Johns Hopkins University) and 
obtained from the Developmental Studies Hybridoma Bank (developed under the auspices 
of the NICHD and maintained by The University of Iowa, Department of Biological 
Sciences, Iowa City, IA 52242). Mouse monoclonal antibody raised against 
lysobisphosphatidic acid (LBPA) also known as bis(monoacylglycero)phosphate was a 
generous gift from Prof. Jean Gruenberg (University of Geneva). Rabbit polyclonal anti-PAP 
antibody was generated by our group (Vihko, et al. 1978). Mouse monoclonal anti-Flotillin-
1 (610821) was from BD Biosciences, rabbit polyclonal anti-snapin (Cat.no. 148 002) was 
obtained from Synaptic Systems. Mouse monoclonal anti-smooth muscle β-actin antibody 
(ASM-1) was purchased from Progen Biotechnik, and goat polyclonal anti-ACPP antibody 
(EB09390) was obtained from Everest Biotech. Mouse monoclonal anti-PAP (P5687) and 
rabbit anti-GAD 65/67 antibody (#G5163) were purchased from Sigma-Aldrich. Rabbit 
polyclonal anti-CD13 (ab93897), mouse monoclonal anti-pan cytokeratin (ab6401), rabbit 
polyclonal anti-Ki67 (ab15580), rabbit polyclonal anti-synaptophysin (ab14692), and rabbit 
polyclonal anti-CHMP2B (ab33174) were acquired from Abcam. 
Fluorescent-labeled second antibodies were obtained from Molecular Probes, 
Invitrogen, Life Technologies (Alexa Fluor 594 goat anti-mouse IgG, Alexa Fluor 594 goat 
anti-rabbit IgG, Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 488 goat anti-mouse IgG, 
and Alexa Fluor 488 donkey anti-goat IgG). The TRITC goat anti-mouse IgG was acquired 
from Sigma-Aldrich; and the Texas Red goat anti-rabbit IgG (#31506) was acquired from 
Thermo Scientific. 
Normal goat serum (S-1000) and normal horse serum (S-2000) were purchased from 
Vector laboratories. 
3.2 Ethics Statement (Articles II and III) 
The permissions to use the human and mice specimens for research purposes were 
obtained from Oulu University Hospital´s Ethics Committee and the National Authority for 
Medico-legal Affairs, and from The Animal Experimentation Committee at the University of 
Oulu, respectively.  
The animal protocols were also approved by ELLA - The National Animal 
Experiment Board of Finland. The project license numbers are 044/11 and STH705A / 
ESLH-2009-08353/Ym-2. 
3.3 Mice (Articles II and III) 
PAP-deficient mice were generated in our laboratory by replacing exon 3 
(ACPPΔ3/Δ3) of the prostatic acid phosphatase gene (Acpp, PAP) with the neo gene as 
 37 
 
described earlier by Vihko and collegues (Vihko, et al. 2005).  Briefly, the PAP-targeting 
construct was assembled by placing a neo gene into exon 3 in a 7 kb genomic fragment that 
remained unaltered in the reading frame. The thymidine kinase gene was added after the 
mouse PAP sequence as a negative selection marker. The linearized construct was 
electroporated into embryonic stem cells, and clones were screened for geneticin G-418 and 
ganciclovir resistance. The microinjection method was used to generate chimeric mice, and 
backcrossing to the C57BL/6J strain (Harlan Laboratories Inc.) was carried out for 16 
generations to obtain PAP-deficient mice with a homogenous genomic background. The gene 
modification did not affect the fertility status of PAP-deficient mice. Age-matched C57BL/6J 
mice were used as controls in all the experiments.  
3.4 Mouse samples (Articles II and III) 
Mice were sacrificed by cervical dislocation and their organs were immediately and 
quickly dissected under sterile conditions to avoid cell death and tissue degradation. The 
tissues for RNA isolation were placed in RNAlater solution (QIAGEN) according to the 
manufacturer’s instructions and stored at -70ºC until further use. Tissues for protein isolation 
were quickly frozen in liquid nitrogen and stored also at -70ºC until further use. Samples 
were taken for histological studies and fixed in formalin overnight.  
 Brain samples of mice for frozen sections were taken by first anesthetizing the mice 
with sodium pentobarbital given in a bolus dose of 40 mg/kg of body weight (Mebunat Vet, 
60 mg/ml). The mice were then perfused with 30 ml ice-cold 0.9% saline solution, followed 
by 25 ml ice-cold 4% paraformaldehyde (PFA) prepared in 0.1 M phosphate buffer pH 7.4. 
The brain was dissected and post-fixed on 4% PFA in 0.1 M phosphate buffer pH 7.4 for 2 
h. Finally, brain samples were stored in 20% sucrose solution in 0.1 M phosphate buffer pH 
7.4 at 4ºC until further use.  
Newborn mice were sacrificed by decapitation, and their skins were thoroughly 
washed twice with 70% ethanol as the sterilization method. Each skin was then washed three 
times with sterile phosphate buffer saline pH 7.4 (PBS) and cut in 2 mm by 2 mm pieces in 
sterile PBS and then immediately cultured for primary fibroblast cells. 
3.5 Cell culture (Article I and II) 
The human prostate carcinoma cell lines PC-3 and LNCaP, and the mouse neuronal 
Schwann cells (SW-10) were obtained from the American Type Culture Collection (ATCC) 
and grown according to the ATCC instructions. 
PC-3 and LNCaP cells were sub-cultured in RPMI 1640 medium containing 10% 
fetal calf serum (FCS, Biowest), 2 mM glutamine (Sigma), and 100 U/ml penicillin-100 
μg/ml streptomycin (Sigma). 
Mouse skin fibroblasts of WT and PAP-deficient mice were obtained by culturing 
mouse skin explants. Mouse skin explants (2 x 2 mm) were incubated with (0.5 x) trypsin 
(Lonza) diluted in PBS at 37ºC for 30 min. Trypsin was inactivated by addition of complete 
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medium (DMEM, 10% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml 
streptomycin), and the medium was removed and tissues were left to dry in the Petri dishes 
to allow attachment. The medium was added to the Petri dishes and they were placed in an 
incubator with humid atmosphere at 37ºC and 5% CO2. The culture continued for 10 days, 
and the mouse primary fibroblasts obtained by explant culture were sub-cultured under same 
conditions. 
3.6 Transfection of PC-3 cells (Article I) 
cDNA for human TM-PAP was obtained by RT-PCR using human prostate total 
RNA as a template and primers as follows: 5?-TTAGGATCCACCATGAGAGCTGCACC-
3? and 5?-AATGGATCCGATGTTCCCATAGGATTC-3?. The PCR product was cloned into 
pCR 2.1-TOPO plasmid (Invitrogen). The BamHI restriction fragment from the recombinant 
plasmid, which contained the coding region of TM-PAP was cloned into a pEGFP-N3 (BD 
Biosciences Clontech) plasmid. Restriction digestions and sequencing confirmed the 
direction of the insert and sequence of the construction. PC-3 cells were grown to 80-90% 
confluence and transfected using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s instructions. Transfection (DNA:Lipofectamine, 1:2) was performed at  37°C 
in Opti-MEM medium (Gibco) for 5 h. Cells were incubated in normal growth medium at 
37°C for 24 h before the experiments commenced. 
3.7 Splice variant-specific RT-PCR (Article I) 
Total RNA was isolated using the RNeasy Mini/Midi Kit (QIAGEN) following the 
manufacturer’s instructions. The total RNA from human and mouse tissue specimens, mouse 
fibroblasts, SW10, LNCaP and PC-3 cells were used as a template in the reaction. Reverse 
transcription of total RNA to cDNA and subsequent amplification were performed using the 
GeneAmp RNA PCR kit (Applied Biosystems) according to the manufacturer’s instructions. 
Primers are described in Table 3. 
Table 3. RT-PCR primers 
Samples Gene Forward primer Reverse primer 
Human Full-length ACPP long 5’-ATGAGAGCTGCACCC-3’ 5’-GCTCTGGGCAGATTCAAAAGG-3’ 
Mouse Full-length Acpp long 5’-ATGAGAGCTGTTCCTCTGCC-3’ 5’-AGCCCTGTGAACAGCTCAATG-3’ 
Different mouse 
tissues 
Acpp long  5’-GTATTCCGCACACGACACTAC-3’ 5’-GATACACATCTCTCTGCCAG-3’ 
Human TM-PAP 
transfected  
LNCaP and PC-3 
cells 
the underline  sequence 
is added to generate a 
BamH1 restriction site 
needed in the TOPO-
cloning 
5’-TCATGTATTCTGCGCATG-3’ 5’-AATGGATCCGATGTTCCCATAGGATTC-
3’ 
Human BPH and 
PC specimens 
detection of TM- and 
secreted PAP  
5’- GAGAAGGGGGAGTACTTTGTGG-3’ 5’-GGATTCTCTCTGCCAGCAGAG-3’  
for transmembrane PAP  
5’-CTAATCTGTACTGTCCTCAG-3’ 
 for secreted PAP 
BPH, benign prostatic hyperplasia; PC, prostate cancer. 
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3.8 Histology (Article II) 
Mouse prostates were formalin-fixed and embedded in paraffin. Five μm serial 
sections were stained by hematoxylin and eosin. Evaluation of histology was performed 
following the previously described guidelines (Roy-Burman, et al. 2004). Six to eight mice 
of each age group were analyzed. Images were taken using a Labovert FS microscope (Leica 
Microsystems GmbH) for magnification and Nikon Eclipse E800 with Nikon DS-Ri1 camera 
and NIS-Elements Basic research Version 4.12 computer program (Nikon Instruments 
Europe B.V.). 
3.9 Immunohistochemistry in paraffin sections (Article II) 
Five μm sections of paraffin-embedded mouse tissues were deparaffinized, 
rehydrated and endogenous peroxidases were blocked. When required, antigen retrieval was 
carried out in the microwave, by boiling the samples in 0.01 M sodium citrate buffer at pH 6 
for 10 min. The endogenous peroxidase activity was inactivated by 10% methanol and 3% 
H2O2 in PBS (pH 7.4) for 10 min. Samples were blocked for 30 min and incubated with 
primary antibodies at room temperature for 1 h. Unspecific binding of mouse antibodies in 
mouse tissues was blocked using BEAT™ Blocker Kit (HistoMouse™, Life Technologies). 
Immunohistochemical detection of mouse antibodies was performed with Histomouse Max 
DAB-Kit (Life Technologies) and Vectastain Elite ABC Kit (Vector Laboratories) was used 
for the rabbit antibodies. Specimens were counterstained with hematoxylin. Images were 
taken with a Labovert FS microscope (Leica Microsystems GmbH) and Nikon Eclipse E800. 
3.10 Immunohistochemistry in frozen sections (Article III) 
3.10.1  Sections in slides 
Brain frozen samples were orientated and mounted in optimum cutting temperature 
(OCT) compound, frozen in isopentane and liquid nitrogen, and cut for 
immunohistochemistry (10 μm). The sections were allowed to reach room temperature, and 
the endogenous peroxidase activity was inactivated with 10% methanol and 3% H2O2 in PBS 
for staining. The samples were blocked by a blocking buffer and incubated with primary 
antibody at room temperature for 1 h; the EnVision (DAKO) staining kit and 
diaminobenzidine as chromogen (DAKO) were used for antibody detection. 
3.10.2  Free-floating sections 
The endogenous peroxidase activity was inactivated in the samples with 10% 
methanol and 3% H2O2 in PBS (pH 7.4) for 10 min, and non-specific binding was blocked 
by 10% normal serum in PBS. The brain sections were incubated at room temperature 
overnight with primary antibody followed by three washes with PBS. The samples were then 
incubated with biotin-conjugated secondary antibody at room temperature for 2 h, followed 
by PBS washes and ABC incubation (Vectastain Elite ABC Kit, Product PK-6100, Vector 
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laboratories). The samples development was carried out with 0.05% 3,3’-diaminobenzidine 
and 0.03% H2O2 in PBS. The sections were transferred to objective glasses, dehydrated in 
alcohol series and mounted with Depex (BDH). An Olympus BX40 microscope and DP50 
Digital Camera (Olympus Corporation) were used for image acquisition, and the Adobe 
Photoshop CS2 software (version 9.0, Adobe Systems Incorporated) for brightness and 
contrast corrections. 
3.11 Tunel assay (Article II) 
A Tunel assay was carried out to determine the extent of apoptosis in tissues 
(prostates), paraffin sections were deparaffinized and rehydrated. Terminal deoxynucleotidyl 
transferase–mediated dUTP nick end labeling (TUNEL) staining of the apoptotic cells was 
conducted with FragEL DNA Fragmentation Detection Kit (Calbiochem) following the 
manufacturer’s instructions.  
3.12 Transmission electron microscopy (Article II) 
Tissue samples for transmission electron microscopy (TEM) were fixed in a mixture 
of 1% glutaraldehyde and 4% formaldehyde in 0.1 M phosphate buffer. The samples were 
post-fixed in 1% osmium tetroxide, dehydrated in acetone, embedded in Epon Embed 812 
(Electron Microscopy Sciences) and analyzed at the Biocenter Oulu EM core facility using a 
Philips 100 CM Transmission Electron Microscope with a CCD camera.  
3.13 Immunofluorescence and confocal microscopy (Article I, II and III) 
3.13.1 Tissue samples 
Samples were fixed in 4% paraformaldehyde/2.5% sucrose, mounted on sample 
holders and frozen in liquid nitrogen. Cryosections for fluorescence microscopy were cut at 
-100ºC. Non-specific binding was blocked with appropriate blocking solutions, and the 
sections were incubated with primary antibody overnight. Simultaneous staining or 
sequential staining was used depending on the antibodies’ cross-reactivity. Primary 
antibodies where incubated at 4ºC overnight and secondary antibodies where incubated at 
room temperature for 2 h. Samples were mounted using Vectashield with DAPI (Product #H-
1000, Vector laboratories) and coated with a coverslip. The images were obtained using a 
Leica TCS SP2 AOBS (Leica Microsystems GmbH) equipped with an argon-He/Ne laser 
mounted on an inverted Leica DM IRE2 microscope (Leica Microsystems GmbH). Adobe 
Photoshop CS2 software (version 9.0, Adobe Systems Incorporated) was used to merge the 
images and perform minor brightness and contrast corrections. 
3.13.2 Cell samples 
LNCaP and PC-3 cells that had been grown on coverslips were fixed with 4% 
paraformaldehyde, and permeabilized with blocking buffer (1% BSA/0.2% saponin in PBS). 
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Primary antibodies were incubated at room temperature for 1 h or at 4ºC overnight. 
Incubation with fluorescent-labeled secondary antibodies was carried out at room 
temperature for 1 h. The samples were mounted in Mowiol/DABCO/DAPI solution, and 
confocal images were acquired using an Olympus FluoView 1000 confocal microscope with 
UPLSAPO 60x oil NA 1.35 objective, and 405, 488, and 543 nm laser excitation. 
3.14 Isolation of exosomes (Article II) 
The LNCaP cell culture medium was recovered for the isolation of exosomes 
(Henttu, et al. 1992). Consecutive centrifugations at 500 g for 5 min. and 2000 g for 5 min 
were done to remove cellular debris. Supernatants were then filtered through out a 0.22 μm 
filter to remove any large vesicles. The culture media were then concentrated 35 times using 
AMICON concentrators (10 kDa cut off). The concentrated media were ultracentrifuged at 
100 000 g for 2 h (Beckman Optima LE-80K, 50Ti rotor), the pellets were washed in 1ml 
PBS, and ultracentrifuged again at 100 000 g for 2 h. Finally, the pellets containing the 
exosomes were resuspended in 30 μl PBS and stored at -70ºC for further analysis. 
3.15 Western blot (Article II) 
The concentrations of proteins in the samples were measured using a Pierce BCA 
Protein Assay kit (Thermo) according to the manufacturer’s instructions. Samples were then 
loaded in 7.5% or 12% SDS-PAGE gel (45 min /180V) and blotted onto PVDF membrane 
using a wet blot system (1.5 h/ 200V). The blotted membrane was first blocked with 5% fat-
free dry milk in TBST (Tris-Buffered Saline + 0.1% Tween 20), and then incubated with the 
corresponding antibodies at room temperature for 1 h or at 4ºC overnight. Blots were properly 
washed and incubated with species specific second antibodies conjugated with horseradish 
peroxidase at room temperature for 1 h. Protein detection was performed using a 
chemiluminescent substrate (Super Signal West Pico, Thermo) according to the 
manufacturer’s instructions, and exposing the membranes to autoradiography films 
(UltraCruz, sc-201697, Santa Cruz Biotechnology Inc.). Films where then developed in a 
Kodak Medical X-Ray Processor 102. 
3.16 Proliferation and apoptosis assays (Article II) 
Consecutive 5 μm sections of paraffin-embedded prostatic tissue were either 
proliferation (Ki-67 antibody) or apoptosis (TUNEL technique) stained. Ten random fields 
from each section were photographed by using a Labovert FS microscope (mag. 40 x). Each 
field was counted for proliferative and apoptotic status.   
3.17 Imaging and image analyses (Article II and Article III) 
3.17.1  Co-localization 
Three independent experiments were performed and three different fields were 
analyzed per sample for the co-localization studies. Seven to 13 stack images were acquired 
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for each field using sequential scanning, with an image size of 1024 x 1024 and 500 nm in z-
dimension. Confocal stack images were deconvolved with five iterations using AutoQuantX's 
blind deconvolution algorithm (Media Cybernetics). The 3D co-localization studies were 
performed using Biplane Imaris 7.2 software (Biplane AG) and the automatic threshold co-
localization algorithms developed by Costes et al. (Kilsheimer and Axelrod. 1957). The co-
localization results are expressed as the mean of Pearson’s coefficient ± SEM. 
3.17.2  Brain size analysis 
A blind analysis of brain MRI images was performed to reduce the possibility of 
bias in the experimental results. Using Image J program, the area corresponding to the brain 
was selected from the MRI images using the free-hand selection tool, followed by the 
generation of a mask, which excluded the cerebellum and the olfactory bulbs. An image 
calculation was performed for each slice of the image stack, automatic threshold adjustment 
was applied to the resulting images, the noise was removed and holes were filled. The area 
was calculated in each image slice by using the “analyze particle” tool in image J. The total 
brain volume was estimated as the sum of every area multiplied by the slice thickness. 
Samples were then divided by genotype and age, and the Student’s t test was used to compare 
brain sizes. 
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4. Results 
4.1 PAP is expressed in different tissues (Article I) 
The expression of PAP in mouse tissues and human cells was carried out by RT-
PCR (Figure 5 and Article I Figure 1D). Total RNA and primers hybridizing to the second 
and seventh exon of the ACPP gene were used for the simultaneous amplification of both 
isoforms. PAP expression was detected in mouse tissues such as AP, DLP, VP, SG (salivary 
gland), lung, and kidney. 
4.2 Alternative splicing of PAP gene leads to a novel transmembrane isoform of 
PAP (Article I) 
We queried different databases and compared PAP sequences, and found a transcript 
for mouse PAP that codified a putative longer isoform of the enzyme. We used total RNA 
from rat and human tissues to obtain and compare the new variant by RT-PCR in order to 
determine the presence of this transcript. The analysis of the exon-intron boundaries 
suggested that the PAP variants are generated by alternative splicing of its pre-mRNA 
(Figure 6). The open reading frame in humans continues over the splicing site until the stop 
codon is encountered which forms the short PAP variant, whereas the longer variant is 
Figure 6. Schematic representation for the alternative splicing of ACPP. The lengths of exons, introns, and the 3’-
untranslated region are visible between parentheses. 5ʹ and 3ʹ splice site of introns are in bold letters. The stop
codon is in green. Constitutive exons are shown in violet, alternative spliced exons in orange, and 3’-untranslated
regions with orange stripes. 
Figure 5. Expression of PAP in different mouse tissues and cells. AP, anterior prostate; 
DLP, dorso-lateral prostate; VP, ventral prostate; SG, salivary gland. 
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produced by the reading of a 5? splice site and the splicing of a 10848 bp sequence. The PAP 
variants in the mouse were produced by the splicing of alternative intron10 and exon11 in 
the pre-mRNA (Figure 6).  
Using specific primers for both variants in RT-PCR, we showed their expression 
(TMPAP is 393 bp and SPAP is 326 bp) in different mouse tissues and cells including mouse 
Schwann cells (SW10) and newborn mouse fibroblast (Figure 7 ).  
The long variant transcript in humans coded for a 418 amino acid protein. The NH2 
terminal 32-amino acid long signal peptide is conserved in this new transcript, whereas the 
major differences are located in the COOH-terminus of the enzyme. The analysis of the new 
COOH-terminal sequence predicted the presence of a 22-amino-acid transmembrane domain, 
and an endosomal/lysosomal targeting Y[G/R]NI motif separated by 10 amino acids from 
the transmembrane domain (Article I).  
The complementary DNA (cDNA) for the longer PAP transcript in humans 
(TMPAP) was obtained by RT-PCR using total RNA isolated from human prostate as a 
template. The PCR product was cloned into an appropriate plasmid and a fusion protein with 
enhanced green fluorescent protein (EGFP) was generated. The fusion protein was 
transfected into PC-3 cells to verify the functionality of the new transcript (Figure 8).  
Figure 7. The expression of SPAP mRNA in mouse tissues and cells. DLP, dorso-lateral prostate; VP, ventral
prostate; AP, anterior prostate; SG, salivary gland; Thy, thymus; Fib. fibroblast; SW10, mouse Schwann 
cells.  
Figure 8. Stack images of PC-
3 cells transfected with
TMPAP/EGFP construct. Top:
upper part of the cell;
Botton: bottom of the cell. 
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The expression of these two transcripts was also assayed in pathological prostatic 
tissue by qRT-PCR. The results showed a significant decrease of almost 50% in the 
expression of SPAP mRNA in the well-differentiated prostate cancer samples compared to 
the benign prostatic hyperplasia (BPH), no changes were observed for the TMPAP mRNA 
(Article I).  
4.3 TMPAP is localized in the endosomal/lysosomal pathway (Articles I, II and III) 
The tyrosine motif present in the new PAP isoform (Y[G/R]NI) is very similar to 
previous reported tyrosine motifs (YxxΦ), which are involved in the transport of 
transmembrane proteins to the plasma membrane via AP1. The (Y[G/R]NI) also manifests 
similar endocytosis activity via clathrin-coated vesicles throughout the interaction with the 
AP2 protein (Ohno, et al. 1995). A consideration of the presence of the signal peptide, the 
presence of a second transmembrane sequence, and the tyrosine motif in the COOH-terminus, 
led us to suggest that the new PAP isoform is a transmembrane type I protein (TMPAP) 
which might be recycled from the plasma membrane via the endosomal/lysosomal pathway. 
The topology for TMPAP indicates that its active site (NH2-terminus) is exposed to the 
lumen of the organelles/vesicles when is located in their membranes and/or to the 
extracellular space when is present in the plasma membrane, whereas the COOH-terminus 
faces the cytosol. 
We performed immunofluorescent stains and co-localization studies with several 
organelle markers in cells and tissues to verify our hypothesis of TMPAP being endocytosed 
and later delivered to lysosomes. PAP co-localized with EEA1 (early endosomes antigen 1), 
LBPA (lysobisphosphatidic acid, a marker for multivesicular bodies - MVB) and also with 
LAMP (lysosomal-associated membrane protein) 1 and 2 (both markers for lysosomes), 
which indicated the functionality of the YxxΦ motif in the endocytosis (Figure 9 and from 
Article I Figure 4D). In addition, PAP also co-localized with flotillin 1 (Article I Figure 4C), 
which is considered to be a marker for caveolae related endocytosis (Bickel, et al. 1997).  
PAP has also been localized by immunoelectron microscopy (IEM) in LNCaP to 
lysosomes, endosome-like vesicles and caveosomes-like structures (Article I Figure 3A); and 
in mouse Schwann cells in the plasma membrane and in filopodia (Article I Figure 3B). The 
IEM procedure using specific antibody for PAP and silver enhancement for the detection is 
described elsewhere (Article I). 
We also performed immunofluorescence staining and IEM in human prostate cancer 
samples to further validate our results. The co-localization of PAP with LBPA in the analyzed 
tissues was almost complete, with PAP localizing in vesicle-like structures present in the 
apical and also basal cytoplasm. Strong labeling for PAP and LBPA was also observed in the 
lumen of the gland (Article I Figure 2A). High-resolution images obtained by IEM allowed 
us to identify the presence of PAP attached to the membrane structure of electro-lucent 
vesicles, and also to MVB co-localizing with LBPA (Article I Figure 2B). PAP is also 
localized in the plasma membrane and in membranous structures that are present in the lumen 
(Article I Figure 2C). PAP labels lysosome-like structures and is together with LBPA in 
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endosomal-like structures (Article I Figure 2C). 
We also analyzed mouse brain samples for the presence of PAP and found that PAP 
is also visualized in the vesicle-like structures found in the slices of the striatum, and co-
localized with the synaptic vesicle marker synaptophysin, and the MVB marker CHMP2B 
(Article III Figure 8 A - C and G - I).  
4.4 TMPAP co-localize and interacts with snapin (Articles II and III) 
The generation of the PAP-deficient mouse makes it possible to perform microarray 
studies (collaboration with Prof. Sampsa Hautaniemi’s group) in different mouse tissues (SG, 
prostate, thymus, thyroid) comparing WT and PAP-deficient mice. The analysis of the 
microarrays showed significant changes in ontological groups such as synaptic transmission, 
neuron projection, synapse and synaptic vesicles among others (Article II). 
The combined microarray and co-localization results allowed us to hypothesize that 
TMPAP is involved in vesicular trafficking and it could be interacting with proteins in the 
endosomal/lysosomal pathway. Therefore, we carried out a yeast two-hybrid system assay 
using the COOH-terminus of TMPAP as bate, and we also identified two proteins that 
interacted with TMPAP, namely: snapin and CIB1. Immunofluorescence and co-localization 
studies were performed for these two proteins and PAP to validate these results. We use 
parental LNCaP cells, in which PAP co-localized with snapin, but not with CIB1 (Figure 10, 
unpublished data).  
Figure 9. Co-localization of
PAP with different organelle
markers in LNCaP cells. LBPA, 
lysophosphatidic acid; LAMP1,
lysosomal-associated 
membrane protein1; and
EEA1, early endosomes
antigen 1. 
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Unfortunately, parental LNCaP cells had a low expression of PAP and because this 
cell line is not a clonal line, not all the cells produce similar amounts of PAP for visualization. 
Therefore, we used LNCaP cells generated in our lab that were transfected with TMPAP for 
further co-localization studies. The co-localization between the proteins was observed mainly 
in vesicles-like structures and in the cell membrane (Figure 11). Quantitative analysis of the 
co-localization using the Imaris software produced a Pearson’s correlation coefficient of 
0.485±0.012 when the whole cell was analyzed. However, a clear pattern of localization in 
specific areas of the cell was observed and hence a region of interest (ROI) was stablished 
on these areas to improve the analysis. The quantification of PAP/snapin co-localization in 
the cell lamellipodia had a Pearson's correlation coefficient of 0.680±0.013.  
 The results of the yeast two-hybrid assay and the Pearson’s correlation coefficient 
values led us to conclude that there was a plausible interaction between PAP and snapin. 
Therefore, we used the FRET variant acceptor photobleaching to give in vivo proof of the 
physical protein-protein interaction, which would confirm the PAP-snapin interaction. We 
collaborated with Leonard Khirug's group at the Neuroscience Center (University of 
Helsinki), to perform FRET analysis in LNCaP cells co-transfected with TMPAP-GFP and 
snapin-DsRed constructs. Data analysis revealed significant FRET efficacy between TMPAP 
and snapin (9.3±1%, n = 12 cells) compared to the negative control (−0.4±0.7%, n = 9 cells, 
p<0.0001). In experiments with positive control, the FRET efficacy reached a level of 
37.7±6.5% (Article II). 
In addition to the localization in cells, PAP has also co-localized with snapin in brain 
immunofluorescence stainings of WT mice (Article III Figure 8 D to F). 
4.5 PAP deficiency leads to changes in the prostate and the brain (Articles II and 
III)    
The generation of the PAP-deficient mouse enabled us to study different aspects of 
its physiology, and how the lack of PAP alters normal development in the mouse. Under 
Figure 10. Co-localization of PAP
with snapin and CIB1 in parental 
LNCaP cells. White arrows denote
co-localization. 
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normal housing conditions, PAP-deficient mice develop, mate and behave as WT (C57Bl/6J) 
mice. The PAP-deficient male and female mice are fertile, and the mean litter size was not 
different to that of the WT litters (7.3±2.2 vs 6.3±2, p= 0.16). Nevertheless, we observed that 
the lack of PAP did lead to changes in the prostate (Article II), the brain (Article III), and 
also in fast muscle responses.  
We collaborated with Prof. Pasi Tavi (University of Oulu, unpublished results) to 
analyze the response of fast muscle fibers (flexor digitorum brevis) to electrical stimulation 
in PAP-deficient and WT mice, using Fluo-3 loaded myocytes. The results showed that PAP-
deficient myocytes produced significantly smaller cytosolic calcium signals than WT 
myocytes. For example, a voltage pulse of 50 Hz produced ~30% less calcium in PAP-
deficient myocytes (p<0.001, n=12). However, incremental increases of the stimulatory 
Figure 11. Co-localization studies in TMPAP virus transfected cells. 
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frequency led to increased calcium released by the PAP-deficient myocytes, which indicated 
a relatively normal electrical response. In addition, the calcium uptake by PAP-deficient 
myocytes was significantly slower than that of the WT myocytes, and after a 2 s stimulation 
with 50 Hz the time constant of the calcium decay were 106.5±6.2 ms and 74.2±3.9 ms 
(p<0.001, n=12), respectively. The results revealed an impairment of PAP-deficient 
myocytes regarding calcium release and uptake. However, no further analyses were 
performed to clarify the function of PAP deficiency in muscle fibers. 
4.5.1 The Prostate (Article II) 
PAP had been described largely in the prostate, therefore, we initially focused our 
attention onto this organ and how the absence of this protein can affect its development. 
Evaluation of the three prostatic lobes (AP, VP and DLP) indicated that the lack of PAP 
mainly affects the DLP. However, the phenotype develops slowly over time starting with 
hyperplastic growth at 3-months of age, followed by mouse prostatic intraepithelial neoplasia 
(mPIN) at 6 months and prostate adenocarcinoma at the age of 12 months (Article II Figure 
2A). No changes were observed in the VP or AP at the referred time points (Article II Figure 
1). However, clear alterations were present in the AP of 2-year-old mice, which was 
indicative of localized invasion of the prostate adenocarcinoma (Figure 12).  
All the PAP-deficient mice analyzed at the age of 12 months and older had 
developed prostate adenocarcinoma, which affected some or all the acini in the DLP, similar 
to that found in human pathology. The DLP acini were filled with non-cohesive pleomorphic 
epithelial cells, with enlarged hyperchromatic nuclei and prominent nucleoli (Article II 
Figure 2B). In addition, sites of microinvasion, cribriform structures, and blood vessels 
among neoplastic epithelial cells have been observed. The histological pattern was consistent 
with locally invasive prostate adenocarcinoma. 
The analysis of older mice (24-month-old) revealed the invasion of the surrounding 
stroma in the DLP (Article II Figure 2 C), and also the presence of epithelial cells that filled 
the lumen of the AP lobe (Figure 12). The cells in the AP had lost their cohesion and present 
atypical nucleus with prominent nucleoli, or double nuclei, which was similar to the 
phenomenon observed in DLP lobes at the age of 12 months. The normal morphology of the 
epithelium had been lost and in few areas the cells were still organized as a monolayer. 
Figure 12. Histological changes in AP lobes of 24-month-old WT and PAP-deficient mice; PAP-deficient AP shows
invasion of cells and lack of structure in the epithelium. Scale bars: 100 μm. WT: +/+. PAP-deficient: -/- 
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Despite the changes observed, and the invasion in the surrounding tissue and lobes, we did 
not detect metastatic lesions in organs such as the brain, liver, lungs or lymph nodes.  
Immunohistochemical stainings with a pan cytokeratin antibody confirmed the 
epithelial origin of the cells that had accumulated in the DLP and AP lumen (Article II 
Supplementary figure S1). Moreover, immunohistochemistry of α-smooth muscle actin 
showed the changes in thickness of the fibromuscular sheet, with bulging areas and fusion of 
acini (Article II Figure 3A).  
The accumulation of cells in the gland lumen prompted us to analyze the 
proliferative and apoptotic status of the organ. Even when the percentage of proliferation was 
only 2 to 3% higher in the PAP-deficient mouse than in the WT, the difference between the 
proliferation statuses of the two groups was significant as early as 2-month-old, and was 
sustained over time. However, the apoptosis status was unchanged and did not differ between 
genotypes (Article II, Figure 5).  
We also studied the ultrastructural changes observed in the PAP-deficient mouse 
DLP by transmission electron microscopy (TEM). Changes with age were clearly seen in 
these samples with TEM (Article II Figure 3B) as with classical histological techniques. The 
single cell epithelium presented in WT and in young PAP-deficient mouse DLP was replaced 
by a multilayer epithelium with hyperchromatic nuclei of different shapes and sizes. 
Invaginations of the basal membrane toward the epithelium and the presence of pseudolumen 
were indicative of changes in the cell polarity of the epithelium. The presence of increased 
numbers of electron-lucent vacuoles and also the exocytosis of exosome-like vesicles and 
lamellar body-like structures filled the lumen of membranous material (Article II Figure 4).   
4.5.2 The Brain (Article III) 
PAP-deficient mice have a higher tendency to suffer chronic inflammatory pain and 
neuropathic pain than control littermates, and the intrathecal administration of SPAP exert 
analgesic effects in these animals (Zylka 2008). Thus, the pain-related phenotype present in 
PAP-deficient mice led us to characterize the potential supraspinal functions of PAP.  
Magnetic Resonance Imaging (MRI) was used to examine the brain anatomy of the 
PAP-deficient mice. Coronal and transversal consecutive images clearly showed increased 
lateral ventricle volume in PAP-deficient mice compared to WT mice (Figure 13A), and the 
analysis of the MRI images revealed that PAP-deficient mice had significantly larger lateral 
ventricles than WT mice (p<0.01), but no differences were observed for brain size (Article 
III Figure 1B and C).  
It has been clearly showed that TMPase staining at acidic pH is a specific staining 
for PAP activity (Zylka, et al. 2008, Araujo, et al. 2014). TMPase activity staining of brain 
coronal sections obtained from PAP-deficient and WT mice produced positive staining in the 
striatum of the WT mouse but not in the PAP-deficient mouse (Figure 13B). 
 51 
 
 In addition, IHC stainings that specifically used an antibody raised against PAP 
have shown that PAP is also expressed in the Purkinje cells of the cerebellum (Article III 
Figure 5A), in the substantia nigra pars reticulata (SNpr) (Article III Figure 5B), and in red 
and oculomotor nucleus (Article III Figure 5C). PAP-deficient mouse brain samples were 
used as a negative control to show the lack of specific staining (depict picture in Article III 
Figure 5B). It has been shown by other researchers that the transmembrane isoform of PAP 
in the dorsal root ganglia is the one that exerts the ecto-5'-nucleotidase function (Zylka, et al. 
2008). We were able to clone a full-length TMPAP transcript from striatal neurons by using 
Figure 13. Evaluation of WT and PAP-deficient mouse brain. A.PAP-deficient mouse present enlarged 
lateral ventricles (arrows) compare to WT mouse. T2-weighted coronal and transversal consecutive
images from a 12-motnh-old WT and a PAP-deficient mice. B. Localization of PAP in brain. TMPase activity
staining in striatum sections of WT and PAP-deficient mice (2 WT and to 2 PAP-deficient). 
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commercially available mouse striatal neurons, but no SPAP was detected. Therefore, we 
concluded that the PAP isoform present in the brain is the transmembrane isoform.  
We further characterized the lack of PAP on mouse brain functions by using a set 
of behavioral assays, which showed that PAP-deficient mice exhibited increased anxiety in 
the elevated plus-maze test compared to WT mice (Article II Figure 2A). PAP deficient mice 
also displayed a reduced prepulse inhibition (PPI) of the acoustic startle reflex (Article II 
Figure 2B), which could indicate a disturbance in the sensorimotor gating system. The 
administration of the antipsychotic drug haloperidol, a D2-dopamine receptor antagonist, to 
PAP-deficient mice normalized their response in the PPI assay (Article II Figure 2B). The 
disruptive PPI effect of drugs such as D-amphetamine, ketamine or MK-801 (antagonist of 
NMDA a glutamate ionotropic receptor) is well documented. Therefore, we evaluated the 
action of D-amphetamine and MK-801 on mouse locomotor activity. PAP-deficient mice 
clearly displayed an augmented response to D-amphetamine compared to WT mice (Article 
II Figure 2C), but the response to MK-801 was similar between the animals (Article II Figure 
2D). These results led us to suggest that the disrupted PPI observed in PAP-deficient mice is 
probably an effect of alterations in the dopaminergic system. 
SNpr contains the soma of dopaminergic neurons, whereas the striatum is supplied 
with dopamine by the SN. The expression of PAP in the SNpr and in the striatum, together 
with the disturbed PPI suggested abnormalities in the dopaminergic neurotransmission of 
PAP-deficient mice. Therefore, we analyzed the concentrations of dopamine (DA) and its 
metabolites in the striatum. The DA levels between the genotypes were similar, but the 
concentration of 3,4-dihydroxyphenylacetic acid (DOPAC), its main catabolite, was 
increased by 20% in the PAP-deficient mice compared to the WT mice. Thus, the ratio 
between DOPAC and DA was increased by 30%, which suggested a higher synthesis or 
increased turnover of DA was taking place in the striatum of the PAP-deficient mouse 
(Article III Figure 3). Augmented synthesis of DA was validated by the inhibition of the 
enzyme DOPA-decarboxylase, that converts L-dopa to DA, which lead to a higher 
accumulation of L-dopa in PAP-deficient mice (14%) compared to WT mice (Article III 
Figure 3D). We further characterized the dopaminergic transmission by a series of micro-
dialysis experiments that measured DA, DOPAC or HVA (homovanillic acid), but no 
significant differences were observed in their baseline concentrations between genotypes. 
DA synthesis is regulated by DA D2-autoreceptors, therefore its release is modulated by 
adenosine receptors as has been reported elsewhere (Okada, et al. 1996). We also tested the 
D2-autoreceptors (D2R) by micro-dialysis and the adenosine A1 receptor (AA1R) function by 
administration of haloperidol in the case of D2R and action of specific agonist (GR79236X) 
and antagonist (8-CPT) for AA1R, but no differences were observed between these genotypes 
(Article III Figure 4A and B). In view of the observed changes in DA synthesis, we tested 
the capacity of DA released by stimulating it with high concentrations of potassium or 
amphetamine in the dialysis fluid. DA release stimulated by amphetamine was significantly 
faster in PAP-deficient mice than their WT counterparts, whereas stimulation with potassium 
showed a tendency to be quicker but it did not reach significant values (Article III Figure 
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4C).  
The release of DA can also be modulated by the striatonigral GABAergic feedback 
pathway in addition to its regulation by D2-receptor (Bunney and Aghajanian. 1976). 
Therefore we hypothesized that alterations in the GABAergic transmission can lead to the 
disruption in the dopaminergic system in the PAP-deficient mice. Moreover, the anxiety-like 
behavior of the PAP-deficient mice in the plus-maze test, led us to test the hypnotic effect of 
diazepam in the loss of the righting reflex and we observed that PAP-deficient mice were less 
sensitive than WT mice to the diazepam (Article III Figure 2E), which indicated an alteration 
in the GABAergic system of PAP-deficient mice.    
The anatomical distribution of PAP suggests a localization of the protein in 
GABAergic neurons. Therefore, we performed double immunostaining with antibodies for 
PAP and GABA-specific marker, GAD65/67. These two proteins co-localized in the 
cerebellar Purkinje cells and substantia nigra pars reticulata (Article III Figure 6A to C and 
Figure 5H to K), whereas a moderate co-localization was detected in the striatum, 
hippocampal CA1 neurons and prefrontal cortex (Article III Figure 5D to G, 5L to O and 
Figure 6D to F). Almost all the PAP immunoreactivity was detected in GABAergic neurons, 
thus we analyzed the function of GABAA receptor-mediated inhibition in hippocampal CA1 
pyramidal neurons by whole-cell patch-clamp recordings. The result shows the increased 
frequency of GABAA receptor-mediated mIPSCs (miniature inhibitory post-synaptic 
currents) in PAP-deficient mice compared to WT mice, but no change in the amplitude signal 
was detected (Article III Figure 7). 
We had already established that PAP co-localized with snapin in the brain. 
However, an interesting finding has been the change in the distribution of snapin in the PAP-
deficient mouse brain. Immunofluorescence stainings showed that snapin localizes clearly in 
vesicle-like structures in WT samples, whereas snapin distribution in PAP-deficient mice is 
more homogeneous and covers the whole cytoplasm (Article III Figure 9). 
  
54 
 
5. Discussion  
5.1 New PAP isoform and its localization 
The work performed during this thesis project revealed clear evidence that PAP is 
not just a prostate specific protein but it is broadly distributed throughout the body. The study 
of PAP has centered on its secretory isoform and its relation to prostate cancer for more than 
80 years, even when a minor isoform with a slightly different antigenic determinant has been 
also described (Vihko. 1979, Lin, et al. 1983, Lee, et al. 1991). We showed that the alternative 
splicing of the PAP gene generates two PAP transcripts, which gives rise to the well-known 
secretory isoform and also to a new transmembrane isoform. The TMPAP isoform is widely 
distributed among the tissues, and has a type I transmembrane topology with its NH2-
terminus and active site facing the extracellular space, when the protein is in the plasma 
membrane. However, the NH2-terminus faces the lumen of vesicles/organelles when 
TMPAP is in their membranes.   
The TMPAP possess a tyrosine signal in the cytoplasmic COOH-terminal tail 
YG/RNI, which fulfills the requirements of the lysosomal targeting motif YxxΦ, where Y is 
tyrosine,  x is any amino acidic residue but has a tendency to be hydrophilic, and Φ is a 
hydrophobic bulky amino acid residue (Bonifacino and Traub. 2003). Two of the better 
characterized lysosomal proteins, LAMP1 and LAP, also contain the tyrosine motif YxxΦ in 
their respective COOH-terminus. Isoleucine is the bulky amino acidic present in the tyrosine 
based sequence of LAMP1, and it exerts a strong influence by targeting LAMP1 to the 
lysosomes (Höning and Hunziker. 1995). Interesting, it is also the bulky amino acid in the 
tyrosine motif present in PAP.  
Two different pathways are capable of directing proteins towards the lysosome. The 
first pathway directs the transport of proteins from the trans-Golgi straight to the lysosome. 
The second pathway directs proteins from the trans-Golgi to the plasma membrane, and from 
there the proteins are internalized and then transported to the lysosomes via the endosomal 
pathway (Rohrer, et al. 1996). LAMP1 and LAP (ACP2) are examples of lysosomal proteins 
in these two pathways, and contain the tyrosine motif YxxΦ in their C-terminal tail. The 
residues +2 and +3 of this tyrosine motif also affect the pathway to the lysosomes 
(Obermüller, et al. 2002). Even when the same tyrosine motif YxxΦ can be recognized as a 
basolateral, lysosomal or internalization target motif, the subtle differences in their amino 
acid sequences near to the YxxΦ signal determine which μ-subunit interacts with the protein 
and where it will be delivered. The TMPAP localizes in the plasma membrane, endosomes, 
MVBs and lysosomes, which led us to the conclusion that TMPAP is probably following the 
second pathway of delivering proteins to lysosomes (trans-Golgi → plasma membrane → 
endosome → lysosomes). 
Secretory PAP has 49.1% identity with the NH2-terminal side of LAP (Peters, et al. 
1989, Sharief, et al. 1989), and we also showed in this work (Article I) that there is a high 
degree of homology in the COOH-terminus between TMPAP and LAP. However, the 
 55 
 
maturation of LAP in the lysosomes, cleavage of the active site portion from the 
transmembrane portion, occurs by the action of two proteases acting on the COOH-terminus 
of the enzyme (Gottschalk, et al. 1989). First, the cleavage of the cytosolic tail by a thiol 
protease gives place to the second proteolytic cleavage by an intra-lysosomal aspartyl 
protease (Gottschalk, et al. 1989). The sequence motifs required for the two proteases that 
act on LAP cleavage are absent in TMPAP, which indicates that the cytoplasmic tail of 
TMPAP is retained. This absence probably enables the recycling of TMPAP between 
lysosomes and the plasma membrane. 
Secretory PAP is produced and released in high amounts by the human prostate 
(Ronnberg, et al. 1981, Ahlgren, et al. 1995); therefore, this protein has been mainly studied 
in this organ. The expression analysis for the two PAP splicing variants showed that SPAP 
mRNA is decreased in well-differentiated prostate cancer tissue compared to benign 
hyperplasitic tissue of the prostate, but the TMPAP remained unchanged (Article I). 
However, the lack of a more detailed analysis of the expression of these two transcripts in 
different stages of the prostate cancer and their expression in metastatic lesions makes it 
difficult to draw any conclusions in relation to their influence in prostate carcinogenesis. 
Double immunostaining of PAP and LBPA in well-differentiated prostate cancer 
tissue showed their clear co-localization. LBPA is a lipid that is highly enriched in late 
endosomes and multivesicular bodies (Kobayashi, et al. 1999), therefore the co-localization 
results we obtained suggested that PAP is also in these organelles. MVBs are formed by the 
invagination of the late endosome peripheral membrane, which gives place to internal 
vesicles that are considered to be released in the lysosomal lumen and are subsequently 
degraded. However, MVBs of normal and also cancer cells can release their contents into 
lysosomes or fuse with the plasma membrane and release their contents (exosomes) into the 
extracellular space. The functions of MVBs have been extensively reviewed by Hanson and 
Cashikar (Hanson and Cashikar. 2012). Consequently, the presence of PAP associated with 
membrane in the lumen of the prostate gland could have originated in the fusion of MVBs 
with the plasma membrane, and the release of their vesicular contents into the lumen. The 
overexpression of this new isoform in PC-3 and LNCaP cells allowed us to corroborate the 
functionality of the tyrosine domain present in its cytoplasmic tail by conducting co-
localization studies with different organelle markers. Interestedly, the presence of PAP in 
early endosomes and lysosomes, and the differences in secretion with PSA has been 
previously shown by two different groups (Zondervan, et al. 1986, Catz, et al. 2002, Johnson, 
et al. 2005). However, the analysis of the results is limited to the localization of PAP in the 
organelles and no hypothesis of the transport mechanism of this protein is postulated.  The 
works of Catz and Johnson discussed the co-localization of PAP with VAMP, which is a v-
snare present in secretory vesicles as well as in endocytic vesicles. However, they did not 
discuss the co-localization of PAP with EEA1 and LAMP2, which should not be expected 
from a protein intended just to secretion.  
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5.2 PAP deficiency in an animal model   
5.2.1 Lack of PAP in the prostate and protein interactions 
The development of genetically modified animals has enabled researchers to study 
the biological functions of proteins or their effects in different pathologies. Homologous 
recombination methods have been mainly used in the generation of transgenic mice that carry 
“loss of function” mutations, also known as knockout mice (Hall, et al. 2009). The generation 
of the PAP-deficient mouse by our research group has allowed us to study the effect of PAP 
deficiency in mouse tissues. Microarray data from different tissues (Article II) as well as real 
time PCR assays (unpublished data) determined that PAP expression was highly down 
regulated in the deficient mouse compared to the WT. In addition, Zylka and co-workers 
showed that thiamine monophosphate is a highly specific substrate for PAP at acidic pHs and 
that PAP phosphatase activity is totally lost in the deficient mouse (Zylka, et al. 2008). This 
result was confirmed by histochemical stains of mouse submandibular salivary gland 
(Araujo, et al. 2014). 
The prostate is the main organ in which to study PAP, thus the first analysis that 
was conducted on the PAP-deficient mouse organs was on its prostate. Histological 
examination of the PAP-deficient mouse prostates clearly showed gradual histopathological 
changes in the DLP, which later leaded to the development of the prostate adenocarcinoma. 
The consensus of various research studies consider that the DLP in mouse is analogous to the 
peripheral zone in human prostate (Roy-Burman, et al. 2004, Xue, et al. 1997, Berquin, et al. 
2005), and Roy-Burman and colleagues suggest that genetic modifications that affect the 
DLP of mouse could have a closer relation to the pathologies that arising in the peripheral 
zone of the human prostate (Roy-Burman, et al. 2004). 
Several different genetically modified mice carrying genes related to prostate cancer 
mimic the disease in humans, and even some genetic modifications also mimic the evolution 
of the disease (Hurwitz, et al. 2001). One of the closer mouse models to the human prostatic 
adenocarcinoma has perhaps been the phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN)-knockout mouse. This protein is involved in the regulation of cell 
survival signals by antagonizing the phosphoinositol-3-kinase (PI3K) activity (Song, et al. 
2005), and it is frequently downregulated or absent in human prostate cancer (Vlietstra, et al. 
1998, Yue, et al. 2014). The PTEN mouse model also resembles the disease in humans, but 
the cancer develops in a much shorter time period, and 12-week-old mice with heterogeneous 
background already present metastases in different organs (Wang, et al. 2003). However, the 
genetic background of the mice has an important effect in the onset of the disease, and a 
PTEN mouse model established in a homogeneous C57BL/6J (Jackson Laboratory) mouse 
background shows basically the same changes but the disease develops at a slower pace (with 
mPIN at the age of 2 months and invasive adenocarcinoma at the age of 12 months), and no 
metastasis are detected (Svensson, et al. 2011). The PAP-deficient mouse presented similar 
changes and at similar time points as the PTEN (C57BL/6J) mouse and they also share a 
similar mouse background, which strongly suggests that the onset of the disease in our PAP-
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deficient mouse could also be as a consequence of the genetic background. However, the 
PTEN (C57BL/6J) mouse develops the disease in all the prostatic lobes, whereas in our PAP-
deficient mouse the AP is affected much later in the mouse life span and we did not detect 
changes in the VP.  
Among the changes we observed in the PAP-deficient mouse using electron 
microscopy, the increase of exosomes-like vesicles present in the lumen of the gland and 
lamellar-like structures that lead to an increase in the amount of membrane debris in the 
lumen of the gland was detected. These observation correlate with those made in human 
prostate cancer tissue, in which PAP was co-localized with flotillin and LBPA which work 
as an exosome marker (Record, et al. 2011). Plasma from prostate cancer patients exhibits a 
higher content of exosomes compared to healthy donors or patients with BPH (Tavoosidana, 
et al. 2011). In addition, King and co-workers showed that the exosome released by solid 
tumors is increased due to the higher levels of hypoxia inside the tumor (King, et al. 2012), 
which may well explain the presence of these vesicles in the glands of the PAP-deficient 
mouse and in the samples of human prostatic adenocarcinoma. Recently, two studies 
demonstrated the effect of exosomes on tumor development, and that tumors and tumor cells 
have a tendency to release more exosomes than normal healthy tissue (Trerotola, et al. 2015, 
Guo and Guo. 2015). Moreover, exosomes have important functions in cell-cell 
communication and regulation, by carrying biologically active molecules such as 
microRNAs, DNAs, RNAs and proteins (Wang, et al. 2015). A clear example of cell-cell 
communication has been published by Putz and co-workers who demonstrated that the 
transport of PTEN in exosomes allows the protein to reach the target cell, and also retain its 
phosphatase activity (Putz, et al. 2012).  
The microarrays analysis of prostatic tissue revealed changes in the expression of 
genes related to vesicular traffic and neurotransmitter release in the PAP-deficient mouse. In 
addition, we showed that TMPAP co-localized and interacted with the SNARE associated 
protein, snapin. These results when taken together indicate that a disruption of the 
TMPAP/snapin interaction could lead to a disturbed vesicular trafficking and produce the 
observed changes. It has been shown that the interaction of snapin with membrane proteins 
(Wei, et al. 2010) and its phosphorylation status, affect the binding of snapin to the SNARE 
complex, which leads to a differential regulation of the exocytosis (Chheda, et al. 2001, Yun, 
et al. 2013). We hypothesized that the interaction between TMPAP and snapin could decrease 
the availability of snapin for the SNARE complex, which would negatively regulate 
exocytosis. In the absence of TMPAP, however, the system would be deregulated and would 
cause an increase in exocytosis, which is consistent with our observations in the PAP-
deficient mouse.  
The interaction between TMPAP and snapin could also disrupt the interaction 
between the tyrosine motif YxxΦ present in the COOH-terminus of TMPAP and the adaptor 
protein AP2, required for clathrin internalization of membrane proteins (Bonifacino and 
Traub. 2003). This interaction could be regulating the period of TMPAP in the plasma 
membrane, which would affect the levels of adenosine via the ecto-5'-nucleotidase activity 
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exerted by TMPAP (Zylka, et al. 2008). Adenosine G-protein couple receptors regulate 
neurotransmission and exocytosis (Golembiowska and Dziubina. 2004), and the generation 
of adenosine could concomitantly affect the activity of its receptors (A1, A2, A3), which 
would lead to changes in the cellular cAMP levels (Uustare, et al. 2006, Hein, et al. 2006). 
This sequence of events would in turn affect the PKA activity, and therefore the snapin 
phosphorylation and its interaction with the SNARE complex (Chheda, et al. 2001). 
5.2.2 Behavioral and neurochemical alterations in the PAP-deficient mouse 
In addition to its function in prostate (Article II), PAP also exerts effect in leukocytes 
and lymphatic organs via its ecto-5'-nucleotidase activity (Yegutkin, et al. 2014), mouse 
submandibular gland (Araujo, et al. 2014) and DRG and spinal cord (Zylka, et al. 2008). We 
observed that PAP also has supraspinal functions that are displayed as behavioral and 
neurochemical changes in the PAP-deficient mouse.  
Among the observations made in our PAP-deficient mouse, the enlarged lateral 
ventricles are interesting results since this phenotype is described in several 
neurodegenerative diseases in human such as Alzheimer’s disease (Tang, et al. 2014), 
Parkinson’s disease (Dalaker, et al. 2011), and schizophrenia (McDonald, et al. 2006). As 
mentioned earlier, the background of the mouse strain can exert an effect on the phenotype 
observed, and therefore is important to mention the tendency of C57BL/6J mice to suffer 
spontaneous hydrocephaly compared to other mouse strains (The Jackson Laboratory. 2003). 
This implies that certain mutations could produce a distinct phenotype in C57BL/6J but not 
in other mouse lines, as was the case reported by Dahme and co-authors who found that a 
disruption of the L1gene produced enlarged lateral ventricles in C57BL/6J mice but not in 
the 129/SvEv line (Dahme, et al. 1997). Hence, we have also to consider that the phenotype 
observed in the PAP-deficient mice might depend on its genetic background to a certain 
degree.  
We considered the ecto-5'-nucleotidase activity described for PAP and its function 
through A1-receptor in DRG and spinal cord and speculated that the same effect could be 
involved in the brain. However, no differences in the response to A1-receptor agonist or 
antagonist was observed in the striatal dopaminergic response, which indicated that possibly 
other enzymes that produce adenosine can compensate the lack of PAP in the brain (Schoen 
and Kreutzberg. 1997, Zimmermann. 1996).   
We studied PAP localization in the brain by immunohistochemistry and 
immunofluorescence, and showed that the protein is expressed in areas such as the Purkinje 
cells of the cerebellum, in the substantia nigra pars reticulata, in the red nucleus and in the 
oculomotor nucleus. However, tested antibodies raised against PAP could not differentiate 
between SPAP and TMPAP, therefore we cloned a full-length TMPAP transcript from the 
mouse striatal neurons to verify TMPAP expression but we did not detect any SPAP 
transcript (Article III). This is in agreement with the results obtained by Zylka and co-workers 
who used in situ hybridization in DRG, and only detected the TMPAP transcript (Zylka, et 
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al. 2008). These results suggest that unlike the prostrate it is possible that the main isoform 
for PAP in the nervous system is the transmembrane isoform.  
We have previously showed that TMPAP is targeted at the endosomal/lysosomal 
pathway via the YxxΦ tyrosine motif, and TMPAP localizes in MVB, lysosomes and 
exosomes (Articles I and II). Our results suggest that TMPAP in the brain is also localized in 
vesicles and it co-localized in MVB with CHMP2B.  MVB in the neurons are involved in the 
recycling and degradation of pre- and post-synaptic membrane proteins, and in the recycling 
of membranes (Saftig and Klumperman. 2009). In addition, the finding that TMPAP co-
localized with synaptophysin and snapin, suggests that TMPAP localizes in the nerve 
endings. This conclusion agrees with previous localization studies in the DRG neurons 
(Zylka, et al. 2008) and co-localization observed in the taste buds of the tongue (Dando, et 
al. 2012). We detected the interaction between TMPAP and snapin in the lamellipodia in 
LNCaP cells (Article II), which allows a parallel to be drawn between nerve endings where 
synapses take place and lamellipodia, because in migrating mammalian cells the 
lamellipodium is the main place of exocytosis (Zuo, et al. 2006, Schmoranzer, et al. 2003).  
We also found that TMPAP co-localized with GAD65/67 in the prefrontal cortex, 
Purkinje cells, striatum, substantia nigra pars reticulata, and hippocampal CA1 neurons. 
Interestingly, TMPAP immunostaining was almost exclusively located in a subset of 
GABAergic neurons, and primarily in the axon hillock, where GABAergic synapses are 
usually placed (Ruigrok and de Zeeuw. 1993). The lack of PAP in the PAP-deficient mice 
produced a mislocalization of snapin, which may affect the normal vesicular trafficking and 
perturb the release and recycling of neurotransmitters leading to the neurochemical changes 
observed in this mouse. Moreover, GABAergic neurons regulate the development of the 
lateral ventricles (Ohtsuka, et al. 2013), and then alterations in the GABAergic transmission 
could explain the increased size in the lateral ventricles of the PAP-deficient mouse.   
The alterations in the PPI, the increased synthesis of dopamine, and the effect of 
amphetamine in the locomotor activity of the PAP-deficient mouse suggest altered 
dopaminergic response in this mouse model, which could be produced by changes in the level 
of dopamine receptors or by an indirect mechanism that controls dopamine release. However, 
the haloperidol-induced dopamine release produced similar results in both mouse genotypes, 
which implies that the D2-receptor expression that controls DAergic transmission was also 
similar between WT and PAP-deficient mice, and also indicates that an indirect mechanism 
that probably affected the release of DA is involved. This conclusion was further supported 
by the effect of amphetamine on striatal dopamine release, which was faster in the PAP-
deficient mouse than in the WT counterpart. This in turn implies that the depressive effect of 
amphetamine on the firing rate of DAergic neurons through the striatonigral GABAergic 
feedback loop (Bunney and Aghajanian. 1976) can be altered. Furthermore, a whole-cell 
patch-clamp assay of the hippocampal CA1 pyramidal neurons showed an increment in the 
frequency of mIPSCs in the PAP-deficient mouse compared to the WTs, which could indicate 
either higher numbers of GABAergic synapses or an increase in the GABA release. These 
results indicated an increase in the GABAergic tone in the PAP-deficient mouse because 
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under these conditions the allosteric-up modulation of the GABAA receptors is probably less 
efficient. This finding was in agreement with the decrease sensitivity to diazepam observed.  
Several mouse models of neurological disorders show GABAergic dysfunctions and 
changes in the inhibitory circuits of the brain (Marin. 2012). We consider that the absence of 
TMPAP in the PAP-deficient mouse leads to the dysregulation of vesicular trafficking which 
might influence the GABAergic transmission and produce the neurological alterations 
observed. 
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6.  Conclusions, conjectures and comments 
The research done for this thesis shows the importance of studying the physiological 
function of proteins and their distribution in the body. One protein, PAP, was mainly studied 
in relation to the prostate and for the diagnosis of prostate adenocarcinoma. The levels of 
PAP in semen can reach 1 to 1.5 mg/ml, and even with such high protein concentrations no 
clear function for PAP has been described in relation to fertilization. The amount of a protein 
present in a tissue can be coincidental thus does not necessary give reliable information about 
how important that protein is for that tissue.  
We investigated the physiological function of PAP and encountered its 
transmembrane isoform, which has lately opened up entirely new lines of research in the field 
of neuroscience. In addition, the generation of the PAP-deficient mouse also facilitates the 
research related to PAP and that PAP is the TMPase that has been used as marker for primary 
nociceptive neurons in DRG and the spinal cord for more than 50 years.  
Despite the achievements of this research project, a demanding amount of work is 
still required to clarify PAP function fully, and especially the function of each of its isoforms. 
It would be interesting to determine clearly the expression of each isoform in normal and 
pathological prostate tissue and how their expressions change in relation to the pathology. At 
the molecular level, mutations in the tyrosine motif of TMPAP could also help us to 
understand and further confirm its intracellular pathway. In addition, we observed that the 
tyrosine motif present in PAP can also fulfill the motif YxNx, and when the tyrosine in this 
motif is phosphorylated can bind to Grb2. The Grb2 protein is known to be an adaptor protein 
that is able to interact with a broad spectrum of membrane and cytosolic proteins. The binding 
of Grb2 to the YxNx present in PAP could therefore lead to the activation of the Ras pathway 
and its downstream kinases Erk1/2 that are involved in cellular functions such as 
proliferation, gene expression, differentiation, mitosis, cell survival, and apoptosis. However, 
Gbr2 also interacts with Cbl1 and promotes protein ubiquitination. The PAP protein presents 
a single lysine residue in its cytoplasmic tail that could be ubiquitinated, which could lead to 
an internalization pathway that is different to that described in the present thesis. Whether or 
not the tyrosine motif present in the TMPAP isoform is phosphorylated could, therefore turn 
to be a major issue of analysis: especially regarding which kinase could be acting and which 
are the possible downstream effects.    
Furthermore, the deficiency of PAP in PAP-deficient mouse model leads to 
increased amounts of phosphatidylinositol-4,5-biphosphate in the DRG, thus it would be 
interesting to determine the status of phosphatidylinositol-4,5-biphosphate in the different 
organs of the PAP-deficient mice compared to WTs. This approach might help to explain 
some of the phenotypes observed in this mouse model. 
Clearly, we are far from fully understanding all the functions of this protein and its 
actions, discovered and undiscovered, in the different tissues. The comprehension of the 
physiological role of proteins in cells and tissues, their interactions, and their regulations will 
certainly help us to understand how a whole organism works and enable us to understand the 
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origin of certain pathologies in addition to their treatment.  
Finally, during the progress of this thesis I have also learnt technical, management 
and interpersonal skills, but what I consider more important is to have learnt that a real 
scientist is the one that questions all the results, his own results and those of others and never 
stops questioning.  
 “When I speak of reason or rationalism, all I mean is the conviction that we can 
learn through criticism of our mistakes and errors, especially through criticism by others, 
and eventually also through self-criticism. A rationalist is simply someone for whom it is 
more important to learn than to be proved right.” 
Karl Popper in “All Life is Problem Solving” (1999)  
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